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ABSTRACT 
 
MULTIFUNCTIONAL CONJUGATED POLYMER NANOPARTICLES AS AN 
ANTICANCER DRUG CARRIER AND A FLUORESCENT PROBE FOR CELL 
IMAGING 
 
ÖZLEM GEZİCİ 
M.S. in Chemistry 
Supervisor: Assoc. Prof. Dr. Dönüş TUNCEL 
July, 2012 
 
The main motivation of this study is to develop multifunctional nanoparticles which can 
perform simultaneously the drug delivery and cell imaging tasks. To this end, firstly 
nanoparticles (Nps) with an average diameter of about 25 nm and based on a green 
emitting, hydrophobic conjugated polymer, poly[(9,9-bis{propenyl}fluorenyl-2,7-
diyl))-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PPFBT) and Nps with an 
average diameter of about 150 nm and based on a red emitting, hydrophobic conjugated 
polymer, poly[(9,9-bis{3-azido-propyl}fluorenyl-2,7-divinylene)-co-(1,4-benzo-
{2,1,3}-thiodiazole)] (PAPFVBT) were prepared, characterized and their convenience 
as a fluorescent probe for cell imaging was evaluated via in vitro cell assays.  
Then, drug loaded nanocapsules in which PPFBT or PAPFVBT acts both as a 
fluorescent reporter and the main matrix of the nanocapsules accommodating an anti-
cancer drug, camptothecin (CPT), were synthesized through a facile, single step 
reprecipitation method. CPT is a hydrophobic, water-insoluble drug but the 
encapsulation improved its water-solubility. The CPT loading efficiency in the 
nanoparticles has been determined to be 100% when a drug to polymer ratio of 1:25 
(w/w) was used. Cell viability of Human hepatocellular carcinoma cell line (Huh7) was 
investigated in the absence and presence of CPT using Sulforhodamine B (SRB) assay. 
SRB assay results supported further by the fluorescence microscope cell images clearly 
confirmed that blank and CPT-loaded PPFBT Nps have been taken up by the cells very 
efficiently and these nanoparticles were accumulated in the cytoplasm. Time and dose 
dependent SRB assay results indicate that the blank PPFBT Nps are not toxic to the 
Huh7 cells up to 25 µM. However, even a very low dose of CPT was found to be 
sufficient to induce the apoptosis of the cells when it was delivered through 
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nanoparticles. Thus, at the end of 48 h, the half maximal inhibitory concentration (IC50) 
of free CPT and CPT-loaded PPFBT Nps were calculated to be 0.9 µM and 0.1 µM 
respectively, corresponding to that CPT-loaded PPFBT Nps are 9 times more effective 
than free CPT.  However, at the end of 72 h, the IC50 of free CPT and CPT-loaded 
PPFBT Nps decreased to 0.1 µM and 0.008 µM, respectively. In this case, CPT-loaded 
PPFBT Nps are 12.5 times more effective than free CPT in inducing the apoptosis of 
Huh7 cells. Although the free drug (CPT) reaches IC50 of 0.1 µM after 72 h, it is 
possible to achieve this value with CPT-loaded Nps at the end of 48 h. On the other 
hand, dose dependent SRB assay results indicate that the blank PAPFVBT Nps are not 
toxic to the Huh7 cells up to 16 µM. At the end of 72 h, IC50 of free CPT and CPT-
loaded PAPFVBT Nps were calculated to be 0.03 µM and 0.1 µM respectively, 
corresponding to that CPT-loaded PAPFVBT Nps are 3.3 times less effective than free 
CPT. Having bigger size (~150 nm) of PAPFVBT Nps is the main reason of not being 
effective as PPFBT Nps (~25 nm). 
 
Keywords: Conjugated polymer nanoparticles; drug delivery; fluorescent imaging 
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ÖZET 
 
ANTİKANSER İLAÇ TAŞIYICI  VE HÜCRE GÖRÜNTÜLEME  
YAPABİLECEK FLÜORESAN KONJUGE POLİMER BAZLI ÇOK 
FONKSİYONLU NANOPARÇACIKLAR  
 
ÖZLEM GEZİCİ 
Kimya, Yüksek Lisans 
Tez Yöneticisi: Doç. Dr. Dönüş TUNCEL 
Temmuz, 2012 
 
Bu çalışmanın temel motivasyonu aynı anda ilaç taşıma ve hücre görüntüleme 
görevlerini gerçekleştirebilen çok fonksiyonlu nanoparçacıklar geliştirmektir. Bu amaca 
yönelik öncelikle, yeşil ışıyan, hidrofobik konjuge polimerden, poli[(9,9-
bis{propenil}florenil-2,7-dil))-ko-(1,4-benzo-{2,1,3}-tiyadiazol)] (PPFBT), 25 nm 
çapında ve kırmızı ışıyan, hidrofobik konjuge polimerden, poli[(9,9-bis{3-azido-
propil}florenil-2,7-divinilen)-ko-(1,4-benzo-{2,1,3}-tiyadiazol)] (PAPFVBT), 150 nm 
çapında nanoparçacıklar hazırlanıp karakterizasyonları yapıldıktan sonra, bunların hücre 
görüntüleme amaçlı flüoresan probu olarak uygunlukları in vitro hücre deneyleriyle 
değerlendirilmiştir.  
Daha sonra, PPFBT veya PAPFVBT polimerlerinin hem flüoresan raportörü olarak 
davranan hem de bir anti-kanser ilacı olan kamptotesini (CPT) barındıracak ana matrisi 
oluşturdukları ilaç yüklü nanokapsüller, basit ve tek aşamalı çöktürme yöntemiyle 
sentezlenmiştir. CPT, hidrofobik ve suda çözünmeyen bir ilaç olmasına rağmen 
kapsüllemeyle suda çözünürlüğü geliştirilmiştir. Nanoparçacıklara CPT yükleme 
verimi, ilacın polimere kütlece oranı 1:25 olduğu zaman %100 olarak belirlenmiştir. 
CPT varlığında ve yokluğunda insan hepatoselüler karsinom hücre hattının (Huh7) 
hücre canlılığı Sülforodamin B (SRB) testi kullanılarak incelenmiştir. Flüoresan 
mikroskop hücre görüntüleri ile desteklenen SRB testi sonuçları ile boş ve CPT yüklü 
PPFBT nanoparçacıklarının hücreler tarafından çok etkili şekilde alındığı ve bu 
nanoparçacıkların sitoplazmada biriktiği açıkça tespit edilmiştir. Zaman ve doza bağlı 
SRB testi sonuçları boş PPFBT nanoparçacıklarının 25 μM değerine kadar Huh7 
hücreleri için toksik olmadığını göstermiştir. Bununla birlikte, çok düşük dozda 
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kamptotesinin bile bu nanoparçacıklar kanalıyla sevk edildiğinde hücrelerin apoptozunu 
teşvik etmek için yeterli olduğu bulunmuştur. Böylece, 48 saat sonunda, serbest CPT ve 
CPT-yüklü PPFBT nanoparçacıklarının yarı maksimal inhibitör konsantrasyonu (IC50) 
sırasıyla 0.9 μM ve 0.1 μM olarak hesaplanmış ve CPT-yüklü PPFBT 
nanoparçacıklarının serbest kamptotesine göre 9 kat daha etkili olduğu belirlenmiştir. 
Ancak, 72 saat sonunda, serbest CPT ve CPT-yüklü PPFBT nanoparçacıklarının IC50 
değerleri sırasıyla 0.1 μM ve 0.008 μM miktarlarına düşmüştür. Bu durumda, CPT-
yüklü PPFBT nanoparçacıkları Huh7 hücrelerinin apoptozunu indükleyecek şekilde 
serbest kamptotesine göre 12.5 kat daha etkilidir. Serbest ilacın (CPT) 72 saat sonra 0.1 
μM IC50 değerine ulaşmasına rağmen, 48 saat sonunda CPT-yüklü nanoparçacıklar ile 
bu değeri elde etmek mümkündür. Diğer taraftan, doza bağlı SRB testi sonuçları boş 
PAPFVBT nanoparçacıklarının 16 μM değerine kadar Huh7 hücreleri için toksik 
olmadığını göstermiştir. 72 saat sonunda, serbest CPT ve CPT-yüklü PAPFVBT 
nanoparçacıklarının IC50 değerleri sırasıyla 0.03 μM ve 0.1 μM olarak hesaplanmış ve 
CPT-yüklü PAPFVBT nanoparçacıklarının serbest kamptotesine göre 3.3 kat daha az 
etkili olduğu belirlenmiştir. PAPFVBT nanoparçacıklarının (~ 150 nm) büyük boyuta 
sahip olması PPFBT nanoparçacıkları (~ 25 nm) kadar  etkili olmamasının başlıca 
nedenidir. 
 
Anahtar Kelimeler: Konjuge polimer nanoparçacıklar; ilaç taşıma; flüoresan 
görüntüleme. 
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CHAPTER 1. INTRODUCTION 
1.1. Conjugated Polymers 
Conjugated polymers possess a unique set of properties such as conductivity, 
photoluminescence, electroluminescence and electrochromism. Therefore, they have 
been used for optoelectronic applications, such as light-emitting and photovoltaic 
materials, thin film transistors and chemo/biosensors.
1,2
  
In fact, there are two Nobel prizes in chemistry for the research on conjugated 
polymers. Firstly, the discovery on conducting electricity of ―doped‖ polyacetylene by 
Professors Alan Heeger, Alan MacDiarmid, and Hideki Shirakawa has been awarded 
the Nobel Prize for Chemistry in 2000.
3
 Secondly, the invention of novel palladium-
catalyzed cross couplings that can be used for the synthesis of organic materials and 
conjugated polymers by Professors Richard F. Heck, Ei-ichi Negishi, and Akira Suzuki 
has been awarded the Nobel Prize for Chemistry in 2010.
4
 
The electronic structure of a material determines the electrical properties. For example, 
the orbitals of the atoms in metals overlap with the equivalent orbitals of their 
neighbouring atoms in all directions to form molecular orbitals similar to those of 
isolated molecules to form an apparently continuous band of energies (Figure 1.1).
3
 
 
Figure 1.1. Simple band picture explaining the difference between an insulator, a 
semiconductor and a metal.
3
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Furthermore, the semiconductor like property of conjugated polymers comes from the 
fact that all conjugated polymers have delocalized π-electrons across all the adjacent 
aligned p-orbitals meaning that these electrons are not a part of one valence bond 
(Figure 1.2).
1,5
  
 
Figure 1.2. Delocalized π-bonds in conjugated polymers. 
As shown in Figure 1.3, the conjugation length determines HOMO/LUMO levels. 
When the conjugation length increases, the HOMO level increases, the LUMO level 
decreases, so the band gap decreases. Moreover, these levels and the band gap are 
controlled by type of conjugated system and electron donating/withdrawing groups.
6
 
While electron donating group increases these energy levels, electron withdrawing 
groups decreases the levels. The presence of twists in the polymer structure generally 
decreases the effective conjugation length and therefore increases the band gap.
7
 
 
Figure 1.3. The conjugation length determines HOMO/LUMO levels.
7
  
The alternative donor-acceptor copolymers provide the expansion of the spectral 
absorption in which they are synthesized by introducing electron-donating and electron-
withdrawing units that finds application in photovoltaic materials.
8-10
 Pei et al. 
3 
 
synthesized a low band gap donor-acceptor copolymer based on polyfluorene by Heck 
type of cross coupling polymerization.
11
 They introduced a thiophene unit as a 
conjugated bridge between the electron-donating fluorene unit and electron-accepting 
benzothiadiazole unit that resulted in a broad absorption and low band gap. This study is 
an example of tuning the physical properties of copolymers by changing the donor or 
acceptor units and the linking bridge between them. 
Actually, the extension of the absorption and decrease in the band gap are the results of 
absorption of photons with long wavelengths by the state of internal charge transfer 
from donor to acceptor inside the copolymer. The most commonly used electron-
donating units are thiophene
6
, fluorene
11
, pyrrole
12
 and carbazole
13
 while the most 
commonly used electron-withdrawing units are quinoline
14
, quinoxaline
15
 and 
pyridazine
16
. Polyfluorene and its derivatives have been extensively used as a new class 
of organic semiconductors due their superior optoelectronic properties such as high 
charge carrier mobility.
17,18
 In order to use these semiconductor type of polymers 
efficiently in sunlight harvesting as organic solar cells, the band gap should be narrow 
respect to the maximum photon flux of sunlight (~1.7 eV).
19
 One way to make narrow is 
the incorporation of the electron-withdrawing unit into polyfluorene chains to form an 
alternating donor-acceptor copolymer.
11
 A typical solar cell is illustrated in Figure 1.4. 
 
Figure 1.4. Typical solar cell. a, Polymer bulk-heterojunction. The bottom transparent 
substrate can be glass or flexible plastic, the bottom contact is a transparent conducting 
oxide (TCO) with a high work function, the active layer is a mixture of donor and 
acceptor molecules, and the top electrode is a metal with a low work function, such as 
aluminium. Reprinted with permission from ref. 20 (Copyright 2009, Nature Publishing 
Group). 
4 
 
Conjugated polyelectrolytes are different from the normal ―neutral‖ conjugated 
polymers because of the presence of ionic side group attached to the conjugated main 
chain.
21
 As previously discussed, the first common component, π-conjugated backbone, 
determines the main optical properties such as absorption and emission spectra, so the 
light-harvesting ability. The second component, charged side-chains, provides water 
solubility that can interact with biomacromolecules, microorganism, or cells (Figure 
1.5). The charged side-chain could be cationic quaternary ammonium groups, sulfonic 
groups, anionic carboxyl groups, or phosphate groups.
22
 
 
Figure 1.5. Schematic representation of conjugated polyelectrolytes for imaging, 
diagnosis and therapy. Reprinted with permission from ref. 22 (Copyright 2012, 
American Chemical Society). 
Pu et al. designed two multicolor light-up probes from two cationic conjugated 
polymers for biomolecular quantification (Figure 1.6).
23
 The idea was the enhancement 
of fluorescence, which is weak in aqueous media because of the charge-transfer 
electronic states of the polymers, by increasing the hydrophobicity of polymeric 
environment through complexation with biomolecules. Both cationic polymers showed 
an increase in fluorescence turn-on responses toward bovine serum albumine (BVA) 
and DNA resulting in biomolecule-dependent light-up signatures. The larger light-up 
response was shown by the polymer with vinyl linkages along its backbone because of 
the stronger charge-tranfer character.
24
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Figure 1.6. Chemical structures of PFBT and PFVBT and the photographs of the 
corresponding fluorescent polymer solutions in the absence (up) and presence (bottom) 
of DNA or BSA with the concentration of 1.2 μM under UV radiation at 365 nm. 
Reprinted with permission from ref. 23 (Copyright 2012, American Chemical Society). 
Although, the unique properties of conjugated polyelectrolytes provide many new 
opportunities for the use in biological applications
25,26
, they can be used in the 
fabrication of polymer light-emitting diodes (PLEDs)
21
 besides the use of neutral 
conjugated polymers for PLEDs
27
. However, the incorporation of ionic side chains 
increases the solubility in water and polar organic solvents, so more environmentally 
friendly producing opportunities are provided.
5
 Furthermore, Mwaura et al. 
demonstrated the fabrication of active materials for organic photovoltaic cells from two 
conjugated polyelectrolytes in which anionic sulfonate solubilizing groups were used as 
the electron donors and cationic methanofullerene was used as the electron acceptor 
(Figure 1.7).
28
 
 
Figure 1.7. Schematic representation of the photovoltaic cell structure showing the 
alternating donor (D) and acceptor (A) layers, forming the active material. Reprinted 
with permission from ref. 28 (Copyright 2005, American Chemical Society). 
6 
 
1.1.1. Synthesis Methods of Conjugated Polymers 
Although superior properties of conjugated polymers, the synthetic methods make 
tricky the control over molecular weight and polydispersity, in other words the 
uniformity of the sample weights
7
. Actually, the polymerization reactions go through 
step-growth mechanism in which bifunctional or multifunctional monomers react to 
form first dimers, then trimers, then longer oligomers and eventually long chain 
polymers (Figure 1.8). As a result of step-gowth polymerization, broad molecular 
weights are obtained that the molecular weight is dependent on the purity of the 
monomer. Therefore, there could be a batch-to-batch variability, so the variation of 
optoelectronic properties. 
 
Figure 1.8. Cartoon representation of step-growth polymerization. 
The common synthetic methodology is the cross-coupling reactions via different 
organometallic reagents. There are many examples in the history such as  the reaction of 
organomagnesium reagents with aryl or alkenyl halides catalyzed by Ni(II) complexes, 
the cross-coupling of Grignard reagents with 1-halo-1-alkenes catalyzed by Fe(III) 
complexes.
29
 Moreover, many other organometallic reagents  such as organolithiums, 
organostannans, 1-alkenylcopper and organosilicon compounds have proven to be 
highly useful as nucleophiles for the cross-coupling reactions.
29
 
The cross-coupling reactions of organometallics have a general catalytic cycle, shown 
in Figure 1.9. It mainly involves three sequences which are oxidative addition, then 
transmetalation, followed by reductive elimination. Most of the cross-coupling reactions 
catalyzed by Ni(0) and Pd(0) are relied on this common catalytic cycle.
29
 
7 
 
 
Figure 1.9. A general catalytic cycle for cross-coupling. Adopted from ref. 29. 
As it is said before, the development of methods for novel palladium-catalyzed cross 
couplings, i.e. the formation of carbon-carbon bonds by Professors Richard F. Heck, Ei-
ichi Negishi, and Akira Suzuki has been awarded the Nobel Prize for Chemistry in 
2010. It is very important to synthesize carbon-carbon bonds for obtaining organic 
materials, complex molecules and conjugated polymers, so the research on this subject 
throughout the history has been awarded the Nobel Prizes in Chemistry; the Grignard 
reaction (1912), the Diels-Alder reaction (1950), the Wittig reaction (1979) and olefin 
metathesis to Y.Chauvin, R. H. Grubbs and R. R. Schrock (2005).
4
 
The wide range of Pd(0) catalysts or precursors can be used for cross-coupling reaction. 
The most commonly used one is Pd(PPh3)4, however PdCl2(PPh3)2 and Pd(OAc)2 with 
PPh3 or other phosphine ligands are also efficiently used. These precursors are stable to 
air and readily reduced to active Pd(0) complexes by organometallics or phosphine 
ligands.
29
 In principle, palladium is like a meeting point for carbon atoms, that is 
depicted in Figure 1.10. Through the formation of metal-carbon bonds, two molecules 
are assembled on the metal. As a result of the proximity of carbon atoms, they couple to 
form new carbon-carbon single bond.
30
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Figure 1.10. Palladium-meeting point for carbon atoms. (Scientists have re-created 
discodermolide in a test tube. In one of the critical steps of that procedure, they used  
Negishi’s variant of the palladium-catalyzed cross coupling).30 
One of the basic types of reactivity in palladium-driven catalytic cycles is the Heck-type 
reactivity. In first place, Heck chemistry was adding in situ-generated methly- and 
phenylpalladium halides to olefins in which organopalladium compound was generated 
from an organomercury compound and Pd(II) salt. The overall reaction was not 
catalytic without any additives because of the formation of Pd(0) at the end. Then, Heck 
developed this situation by adding CuCl2 to reoxidize Pd(0). However, he made a 
significant modification in 1972 that organopalladium complex is generated from an 
organohalide and Pd(0) in a so-called oxidative addition.
4
 This reaction is illustrated in 
Figure 1.11 that gives styrene as product. Heck reaction presents a simple way to obtain 
olefins, dienes, other unsaturated compounds with different substituents, and conjugated 
polymers.
31,32
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Figure 1.11. Richard Heck experimented with palladium as a catalyst and linked a short 
olefin to a ring of carbon atoms. When the two meet on the palladium atom they react 
with each other. The result of the reaction is styrene, a fundamental component of the 
plastic polystyrene.
30
  
Negishi’s studies were concentrated on the use of more chemoselective organometallic 
compounds in the palladium catalyzed couplings with organohalides. Firstly, he got 
successful results by using organozirconium or organoaluminium, followed by the trials 
with less reactive organometallic species. However, his biggest development was 
introducing organozinc compounds as coupling partners in 1977.
4
 Figure 1.10 shows the 
artificially synthesis of discodermolide by Negishi’s type palladium-catalyzed cross 
coupling.  
In 1979, Suzuki presented the use of organoboron compounds in palladium-catalyzed 
cross coupling. As compared to previous ones, boron is the mildest activator and even 
less toxic.
4
 Moreover, the convenience of organoboron compounds comes from being 
thermally stable and inert to water and oxygen, so allowing their handling without 
special precautions.
29
 The organoboron reagents in the presence of a base become 
coupling partners in palladium catalyzed cross couplings to vinyl, aryl and alkyl halides 
in Suzuki reaction.
4
  
The other type of coupling catalyzed by palladium was developed by  John Kenneth 
Stille in 1977. It is the cross-coupling of organotin compounds with an organic 
electrophile, i.e. organohalide, via the catalyzation of palladium. This novel method is 
stereospecific and regioselective in which results in high yields of product.
33
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The mechanisms of commonly employed palladium-catalyzed coupling reactions for the 
synthesis of conjugated polymers are shown in Figure 1.12; Suzuki, Heck, Stille and 
Negishi. 
 
Figure 1.12. Palladium-catalyzed coupling reactions; Suzuki, Heck, Stille and 
Negishi.
34
  
These mechanisms start with the common step, oxidative addition, in which the active 
Pd(0) catalyst react with the organohalide resulting in the change of oxidation state of 
palladium to Pd(II) to form organopalladium compound.
4
 This step is often rate-
determining step in the catalytic cycle that the relative reactivity decreases in the order 
of I > OTf > Br >> Cl.
29
 In the second common step called transmetallation, the organic 
group on organometallic compound is transferred to palladium. However, Suzuki 
mechanism has special case in which the boronic acid must be activated, e.g. with base 
that facilitates transmetallation. By this transmetallation step, the assembly of two 
organic groups on palladium is achieved by palladium-carbon bonds. In the last step, 
two organic groups couple to give a new carbon-carbon single bond. Before this step, 
there is an extra migratory insertion step in Heck coupling that the organic group on 
11 
 
palladium shifts to one of the carbons of the co-ordinated olefin while palladium shifts 
to the other carbon of the olefin to generate carbon-carbon bond. Finally, the release of 
the formed organic compound occur via reductive elimination in all type of reactions 
that proceeds through the reduction of Pd(II) to Pd(0).
4,29,31-33
  
1.2. Conjugated Polymer Nanoparticles 
Nanoparticles are widely used for biological applications such as cell imaging.
35-38
 
However, the most important property for an imaging agent is its photostability that 
most of organic dyes suffer from photobleaching. To overcome this  problem, quantum 
dots (QDs) have been synthesized that they have much greater photostability and 
brightness.
39
 However, they are cytotoxic  since they leach harmful metals.
40
 The use of 
water dispersible conjugated polymer nanoparticles (CPNs) for cellular imaging 
providing more photostability, high fluorescence brightness and lower toxicity has been 
much increased in the recent years.
41-47
 Moreover, they can be synthesized easily with a 
desired emission wavelength and functionalities from a number of different polymers. 
48-52
 These features make them very attractive for photonics
53-55
 and biomedical 
applications. 
41-47,56-60
 
1.2.1. Preparation of Conjugated Polymer Nanoparticles 
Conjugated polymer nanoparticles (CPNs) are generally prepared by two methods; 
reprecipitation and miniemulsion.
61-63
 
The reprecipitation method presented in Figure 1.13 is used to dissolve the hydrophobic 
conjugated polymer in a good (miscible) solvent such as THF or acetonitrile. The 
obtained solution is then poured into a large excess of poor solvents, generally water. 
The formation of nanoparticles driven by hydrophobic interaction is accelerated by 
vigorously stirring and ultrasonication. The water dispersible nanoparticles are obtained 
after the evaporation of the organic solvents. The spherical morphology is the result of 
avoiding the contact of polymer chains with water to get minimum interaction. Unlike 
the miniemulsion method, this process does not involve additives, such as surfactants, 
and the common nanoparticle size is in the range of 5−150 nm in diameter, that depends 
on the concentration of polymer solution and molecular weight of the polymer. This 
method has been applied to a wide variety of conjugated polymers that are soluble in 
organic solvents.
46,48,64
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Figure 1.13. The preparation of nanoparticles using reprecipitation method. 
The miniemulsion method is illustrated in Figure 1.14 that starts with dissolving the 
conjugated polymer in an apolar organic solvent (water immiscible). Then, the polymer 
solution is transferred into an aqueous solution of an appropriate surfactant to avoid 
undesirable coalescence of emulsion droplets. Under the aid of ultrasonication, the 
resulting mixture is drastically stirred to form stable miniemulsions composed of 
polymer droplets. After the evaporation of organic solvent, CPNs are obtained as stable 
dispersion in water. The size range of the resulting CPNs is in between 30 nm and 500 
nm that is dependent on the concentration of polymer solution. 
 
Figure 1.14. The preparation of nanoparticles using miniemulsion method. 
Landfester and co-workers reported the deposition of the layers of conjugated 
semiconducting polymers from aqueous dispersions with controllable particle sizes in 
the range of 70-250 nm prepared by the miniemulsion method.
65
 Using this method, 
Baier et al. demonstrated the preparation of poly-(arylene diethynylene) nanoparticles 
by stepwise polymerization of the corresponding monomers under Glaser coupling 
conditions, then resulted in the tunable emission colors of CPNs by controlling 
intramolecular energy transfer.
66
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1.2.2. Biomedical Applications: Cell Imaging, Drug Delivery, Theranostic 
The diagnosis and therapy of life threatening diseases, such as cancer, present serious 
challenges. In this context, the development of non-invasive methods and materials for 
early cancer diagnosis and efficient drug delivery are highly sought after.  The usage of 
nanomaterials for drug delivery is increased as a result of their high therapeutic efficacy 
while having lower systematic side effects.
67,68
 Various nanostructured-materials in 
different geometries are designed and synthesized from inorganic nanoparticles, 
polymers, lipids and dendrimers to be used as contrast agents, therapeutics, and delivery 
vehicles.
69- 73
 Especially, bioconjugated fluorescent polymeric nanoparticles are widely 
employed in imaging and targeted delivery.
74-76
 
For the preparation of bioconjugates, many kinds of synthetic polymers with structural 
and architectural variations have been recently investigated.
77
 These types are 
monofunctional or polyfunctional linear, starlike and dendritic architectures, depicted in 
Figure 1.15. 
 
Figure 1.15. Selected structural and architectural types of drug–polymer conjugates. 
Reprinted with permission from ref. 77 (Copyright 2006 WILEY-VCH Verlag GmbH 
& Co. KGaA). 
Way et al. developed conjugated polymer nanoparticles conjugated with biorecognition 
molecule, Herceptin, in dendritic-like architecture.
74
 While Herceptin-conjugated 
fluorescent nanoparticles were seen on the HER2-overexpressig cancer cells but not on 
the HER2 basal cells, they could suppress the growth of HER2-overexpressig cancer 
cells. Therefore, these nanoparticles were suitable probes for targeted therapy and 
imaging of HER2-overexpressing cancer cells. Nanoparticles have also been prepared 
14 
 
by Feng et al. for drug delivery through the electrostatic assembly of cationic 
polyfluorene based conjugated polymer with doxorubicin conjugated anionic poly(L-
glutamic acid) in polyfunctional linear fashion.
78
 This complex system could deliver 
doxorubicin to targeted cancer cells while imaging the cells by monitoring doxorubicin 
release based on fluorescence ―turn-on‖ signal of the cationic polyfluorene based 
conjugated polymer. 
Actually, there is an increase in the use of these kinds of theranostic medicine in which 
the diagnosis and therapeutic agents are incorporated into one system to be delivered to 
the cells effectively while following the whole process through appropriate techniques 
with the help of the contrast agents incorporated in the system.
79,80
 However, there are 
no reports on the facile synthesis of drug-loaded conjugated polymer nanoparticles 
through reprecipitation method using only one type polymer and their dual use 
simultaneously for the drug delivery and the imaging.  
The theranostic nanomedicine has many advantages over conventional chemotherapy 
because of a number of reasons. In the latter treatment, the drugs may not approach the 
target easily or be cleared off from the body in a very short time and as a result the 
treatment may require the usage of higher doses of drugs; in turn, this may cause 
unwanted side effects. The nanomedicine has the potential to enable preferential 
delivery of drugs to tumor due to the enhanced permeability and retention (EPR) effect 
is depicted schematically in Figure 1.16, in which the vasculature in tumors is leaky to 
certain sizes of molecules (e.g. liposomes, nanoparticles, and macromolecular drugs) by 
allowing these molecules to accumulate in tumor tissues more than normal tissues.
77,81,82
 
There are two main factors that influence the EPR effect and tumor targeting. Firstly, 
the physicochemical properties of nanoparticles such as the size and surface charge of 
particles influence the their tumor accumulation and pharmacokinetic behaviors. 
Secondly, the tumor properties such as cancer type, stage of disease, tumor size affect 
the tumor targeting properties of nanoparticles.
83
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Figure 1.16. Schematic representation of the anatomical and physiological 
characteristics of normal and tumor tissue with respect to the vascular permeability and 
retention of small and large molecules (EPR effect). Reprinted with permission from 
ref. 77 (Copyright 2006 WILEY-VCH Verlag GmbH & Co. KGaA). 
The cellular uptake and cytotoxicity studies of CPNs based on various conjugated 
polymers have been reported and these studies clearly demonstrated that CPNs were 
taken up efficiently by the cells through endocytosis even in a very short incubation 
time.
46 
Generally, cellular uptake of macromolecules is achieved through receptor-
mediated endocytosis, adsorptive endocytosis, or fluid-phase endocytosis, that is 
illustrated in Figure 1.17. There is significant drop in the pH value that takes place from 
pH 7.2-7.4 in the extracellular space to pH 6.5–5.0 in the endosomes and to around pH 
4.0 in primary and secondary lysosomes. Therefore, it is needed to be sufficiently stable 
of drug–polymer conjugates or complexes in the blood stream before releasing the drug 
at the site of action. The polymer-drug conjugates can be released in the body by 
reduction, or in a pH-dependent manner.
77
 Scherman and coworkers demonstrated the 
synthesis of a supramolecular double hydrophilic block copolymer held together by 
cucurbit[8]uril ternary complexation and its subsequent self-assembly into micelles.
84
 
They encapsulated the the chemotherapeutic drug doxorubicin by this system, then 
investigated the controlled release of the drug through multiple external triggers 
including temperature, pH and the addition of a competitive guest.  
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Figure 1.17. Endocytotic pathway for the cellular uptake of macromolecules and 
nanocarriers for drug delivery. Reprinted with permission from ref. 77 (Copyright 2006 
WILEY-VCH Verlag GmbH & Co. KGaA). 
Howes et al. demonstrated the synthesis of conjugated polymer nanoparticles 
encapsulated by phospholipid micelles that could be used as an imaging agent in 
biomedical applications.
57
 These nanoparticles were firstly used for simple cell imaging 
experiment that  the significance of the result shown in Figure 1.18 comes from their 
deduction on the uptake through endocytosis by observing vesicles of the nanoparticles. 
If nanoparticles were not taken by endocytosis, they expected to observe a uniform 
distribution throughout the cytoplasm. Fernando et al. also suggested the endocytic 
mechanism for the uptake of nanoparticles by observing the intracellular fluorescence 
contained in vesicles.
46
 
17 
 
 
Figure 1.18. Confocal microscope image of SH-SY5Y neuroblastoma cells treated with 
MEH-PPV SPNs for 18 h. The SPNs are seen to cluster in the perinuclear region within 
the cells, suggesting they are in vesicles. The scale bar represents 25 μm. Reprinted with 
permission from ref. 57 (Copyright 2010, American Chemical Society). 
It can be seen in the examples up to this point that for drug-loaded polymer 
nanoparticles, the polymer can form the capsule which hosts the drug molecules inside 
it. However, the controlled release of the contents is important as the encapsulation of 
the drug. In the release of capsule contents, stimuli-responsive phenomenon, i.e. 
triggering plays a key role by causing the change in capsule shell. The mechanisms of 
chemical reactions in polymeric shell wall include triggering by chemical, light, 
biological, magnetic, thermal and electric stimuli. Moreover, there are physical methods 
for the release of capsule content that are shown in Figure 1.19. Firstly, the shell wall 
can rupture by the increase in internal pressure that results in burst. Secondly, the shell 
wall can melt upon temperature increase. Thirdly, core materials are released by the 
change in porosity of the shell wall resulting from a phase transition of a shell wall 
polymer. Diblock copolymer or a mixture of two polymers is needed for this method in 
order to shrink of one polymer while the other one remaining physically intact to create 
the pores upon heating the capsule. Finally, the release can occur through 
thermomechanical degradation of the shell. When mechanical triggering such as 
exposure to magnetic or electrical fields is applied, the nanoparticles start to oscillate 
repeatedly that results in heating and tearing of the shell walls, so the release of core 
materials.
85
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Figure 1.19. Physical methods of capsule release: (A) shell wall rupture by an increase 
in internal pressure, (B) melting of the polymer shell wall, (C) change in porosity of the 
shell wall resulting from a phase transition of a shell wall polymer, and (D) 
disintegration of the shell wall utilizing nanoparticles that oscillate in response to an 
external trigger. Reprinted with permission from ref. 85 (Copyright 2011, American 
Chemical Society). 
1.3. Some Key Concepts 
1.3.1. An anticancer Drug: Camptothecin 
Camptothecin (CPT) is a quinoline alkoloid-based chemotherapy drug for the treatment 
of a broad range of cancers, including human lung, ovarian, breast, pancreas and 
stomach cancers. This anticancer agent kills the cells by converting DNA topoisomerase 
I into a DNA-damaging agent. In a mechanistical look, CPT firstly stabilizes a 
topisomerase I-induced single-strand break in the phosphodiester backbone of DNA, so 
preventing subsequent religation of the broken single strand. During the replication, 
when the DNA replication fork encounters the cleavable complex, it results in an 
irreversible double-strand break, so in an apoptosis. As shown in Figure 1.20, CPT has a 
five-ring structure. The 20S chiral carbon is importatnt for its activity while there is a 
dynamic equilibrium between the closed ring lactone and open-ring carboxylic acid 
forms. In order to be active (cytotoxic), CPT should be in the form of closed ring 
lactone.
86-88
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Figure 1.20. (A) Camptothecin. (B) 20S chiral centre. (C) Dynamic equilibrium of 
camptothecin. (D) Camptothecin sodium salt. (E) Topotecan. (F) Irinotecan. Reprinted 
with permission from ref. 86 (Copyright 2003, Elsevier). 
CPT has poor water solubility and its inactive carboxylic acid form is favoured by 
neutral and alkaline pH. Moreover, this inactive form of CPT promptly binds to human 
serum albumin which hinders its cellular uptake.
86-88
 However, CPT-based drugs, e.g., 
topotecan and irinotecan (Figure 1.20. E and F), are currently approved for use in 
humans despite their adverse side effects due to the solubilizing groups attached to CPT 
backbone. In addition to structurally modified water soluble analogues, special drug 
delivery systems are needed to increase the anticancer efficacy of CPT. The one way is 
to make substitution on 20-OH of CPT that can substantially reduce the tendency for 
lactone ring opening.
88,89
 Botella et al. developed a drug delivery system through the 
attachment of CPT onto silica nanoparticles through an ester bond with 20-hydroxy 
moiety to stabilize the lactone ring.
83
 Feng et al. used click chemistry as a coupling 
method to conjugate CPT and folic acid onto the Janus-type dendrimer-like 
poly(ethylene oxide)s.
90
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Moreover, the encapsulation of CPT by polymeric nanoparticles without any 
conjugation is an another method to overcome the identified shortcomings of CPT.
91
 
Schneider et al. generated biodegradable CPT-loaded polymer microspheres by using 
hydrodynamic flow.
92
 In this study, the cell viability results showed its toxic effects 
indicating that the encapsulated CPT stayed in its lactone form. Other research on the 
encapsulation of CPT was done by Wang et al. that they used block copolymer 
nanoparticles as encapsulating matrix.
93
 According to this study, the encapsulated CPT 
was more effective compared to free drug in inducing apoptotic responses in the 
cultured bone metastatic prostate cancer cells. 
1.3.2. Sulforhodamine B (SRB) Cytotoxicity Test 
It is important to choose a suitable cytotoxicity assay depending on the supposed cell 
death mechanism.
94
 As shown in Figure 1.21, the assays are based on different modes of 
detection like MTT metabolism, LDH release, neutral red uptake and the ATP content 
of treated cells. Keepers and co-workers compared SRB protein stain assay with the 
tetrazolium (MTT) colorimetric assay for in vitro chemosensitivity testing of various 
human tumour cell lines.
95
 They found that the SRB assay provided a better linearity 
with cell number and a higher sensitivity, and its staining was not cell-line dependent. 
 
Figure 1.21. Cytotoxicity assays.
96
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In principle, SRB assay is based on the measurement of cellular protein content for cell 
density determination.The dye sulforhodamine B binds electrostatically and pH 
dependently on cellular protein whose basic amino acid residues were fixed by 
trichloroacetic acid. This binding occurs under mild acidic conditions, however 
solubilization for the measurement occur under mild basic conditions by extracting the 
dye from cells. There is a linear relationship between the results of the SRB assay and 
the cell number and cellular protein. The SRB assay is a nondestructive method by 
having a colorimetric end point and it is indefinitely stable. As a result of these practical 
properties, the SRB assay is appropriate and sensitive to measure drug-induced 
cytotoxicity.
97-100
 
1.3.3. The Half Maximal Inhibitory Concentration (IC50) 
It is extremely important to measure accurately the concentration of the inhibitor by half 
which is required for the inhibition of biological or biochemical function. The half 
maximal inhibitory concentration (IC50) is a quantitative measure of the effectiveness of 
this inhibiton.
101
 The concept of IC50 is shown in Figure 1.22. 
 
Figure 1.22. The half maximal inhibitory concentration. 
In the comparison on toxic properties, IC50 values are very important parameter in 
which smaller values  are the indication of superior inhibiting activity, i.e.,  less amount  
is needed to inhibit the same function by half. The drug delivery system through the 
attachment of CPT onto silica nanoparticles through an ester bond with 20-OH moiety 
developed by Botella et al. has similar IC50 values with the naked drug.
83
 On the other 
hand, Aryal et al. observed superior  therapeutic effect in the cytotoxicity of dual-drug 
(CPT and DOX) carrying nanoparticles compared with their cocktail mixtures.
102
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1.4. Aim of Thesis 
Here it is aimed to synthesize water dispersible, multifunctional nanoparticles which 
can perform simultaneously the drug delivery and cell imaging tasks.  
Firstly, previously synthesized
103
, a green emitting, hydrophobic conjugated polymer, 
poly[(9,9-bis{propenyl}fluorenyl-2,7-diyl))-co-(1,4-benzo-{2,1,3}-thiodiazole)] 
(PPFBT) was used to prepare water dispersible nanoparticles. PPFBT Nps were 
characterized and their cytotoxicity and suitability as a fluorescent marker for cell 
imaging was evaluated in vitro cell assays. Then, drug loaded nanocapsules in which 
PPFBT act both as a fluorescent reporter and the main matrix of the nanocapsules 
accommodating an anticancer drug, camptothecin (CPT), were synthesized through a 
facile, single step reprecipitation method. Actually, to address the solubility problem of 
CPT is highly desirable and one of the objectives of this work is to achieve this through 
encapsulation. To determine the encapsulation efficiency, anthracene (ANT) was used 
besides using CPT. The optimum drug loading capacity of the nanoparticles was 
determined using various ratios of ANT to PPFBT, then CPT to PPFBT. Cell viability 
of Human hepatocellular carcinoma cell line (Huh7) was investigated in the absence 
and presence of CPT using Sulforhodamine B (SRB) assay. Moreover, Huh7 cells 
incubated with PPFBT Nps in the absence and presence of CPT plated concomitantly on 
coverslips and treated identically were Hoechst 33258 stained and examined under a 
fluorescence microscope.  
Secondly, a red emitting, hydrophobic conjugated polymer, poly[(9,9-bis{3-bromo-
propyl}fluorenyl-2,7-divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PBPFVBT) was 
synthesized by incorporating vinyl bonds between fluorene segments and 
benzothiadiazole units within the polymer to get red-shift in the fluorescence. Red 
emitting conjugated polymers have lower energy that make them better for biomedical 
applications such as drug delivery without tissue damage. To eliminate toxic effects, 
bromine group of PBPFVBT converted into azide group resulting in poly[(9,9-bis{3-
azido-propyl}fluorenyl-2,7-divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] 
(PAPFVBT). PAPFVBT Nps were characterized and their cytotoxicity was evaluated in 
vitro cell assays. Then, drug loaded nanocapsules in which PAPFVBT act as the main 
matrix of the nanocapsules accommodating CPT were synthesized. Cell viability of 
Huh7 cells was investigated in the absence and presence of CPT using SRB assay. 
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CHAPTER 2. RESULTS AND DISCUSSION 
This chapter has mainly two parts. The first part consists of the discussion on the 
synthesis and the characterization results of the monomers and polymers.  In the second 
part, the synthesis and characterization of blank and drug loaded nanoparticles are 
discussed followed by cell culture studies. 
This work demonstrates a novel strategy for combination of drug delivery with cell 
imaging without any further need for conventional dyes. The contents of this work is 
illustrated in Figure 2.1.  This drug delivery system is much more simple and efficient 
just by using one kind of polymeric capsule that drug loaded nanoparticles showed 
superior efficacy over free drug. 
 
Figure 2.1. Schematic illustration of this thesis work. 
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2.1.  Synthesis and Characterization of Monomers  
2.1.1. Synthesis and Characterization of  2,7-dibromo-9,9-bis(3-bromo-propyl)-
9H-fluorene (M1) 
2,7-dibromo-9,9-bis(3-bromo-propyl)-9H-fluorene (M1) was synthesized from 2,7-
dibromofluorene and 1,3-dibromopropane according  to  Scheme 2.1. 50% (w/w) NaOH 
solution provided very strong basic condition utilizing the abstraction of weakly acidic 
C9-H. To get the desired monomer, both protons at C9 should be removed. Then, 1,3-
dibromopropane reacted with the resulting anion by adding to 9-position through 
nucleophilic substitution reaction. Although the reaction was exothermic, the 
temperature was kept at room temperature by using ice bath to prevent the formation of 
side products through elimination. The isolation and purification of the product was 
done by work-up with extraction (diethyl ether, distilled water, 2 N HCl) followed by 
column chromatography (cyclohexane as the eluent). The monomer M1 in white 
powders was obtained with 33% yield.  
  
Scheme 2.1. Synthesis of the monomer 2,7-dibromo-9,9-bis(3-bromo-propyl)-9H-
fluorene (M1). 
The structural characterization of the monomer M1 was done by 
1
H-NMR spectroscopy 
shown in Figure 2.2. The signals at 1.6 and 7.3 ppm belong to solvent CDCl3. Then, 
there are four groups of peaks available in the 
1
H NMR spectrum centered around 1.17, 
2.17, 3.14 and 7.5 ppm. It is known that the area under each peak is obtained from 
integration of the signal and is proportional to the number of hydrogen nuclei. The 
integration of each peak at 1.17, 2.17 and 3.14 ppm to 7.5 ppm is nearly 2:3. The 
multiplet at 1.17 ppm labelled as (a) integrates for four protons of methylene next to 
aromatic ring. The triplet at 2.17 ppm labelled as (b) integrates for four protons of 
methylene near to the electron-withdrawing bromine group. The multiplet at 3.14 ppm 
labelled as (c) integrates for four protons of methylene next to the electron-withdrawing 
bromine group. The multiplet at around 7.5 ppm labeled as (d), (e) and (f) integrates for 
six protons of aromatic ring. 
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Figure 2.2. 
1
H-NMR (400 MHz, CDCl3, 25 
o
C) spectrum of  2,7-dibromo-9,9-bis(3-
bromo-propyl)-9H-fluorene (M1) *Denotes for impurities in the solvent. 
2.1.2. Synthesis and Characterization of 9,9-bis-(3-bromo-propyl)-2,7-divinyl-9H-
fluorene (M2) 
9,9-bis-(3-bromo-propyl)-2,7-divinyl-9H-fluorene (M2) was obtained through the 
synthetic route in Scheme 2.2. The monomer M2 was synthesized via Stille coupling by 
heating the mixture of 2,7-dibromo-9,9-bis(3-bromo-propyl)-9H-fluorene (M1) and 
tributylvinyltin in toluene using PdCl2(PPh3)2/2,6-di-tert-butylphenol as catalyst at 100 
o
C for 24 h. Then, the reaction mixture was treated with 10% (w/w) NaF for further 12 h 
at room temperature. The isolation and purification of the product was done by work-up 
with extraction (diethyl ether and distilled water) followed by column chromatography 
(cyclohexane/chloroform, 8/2, as the eluent). For further purification, the monomer 
solution in chloroform was  precipitated into cold methanol to provide white-yellowish 
powder in 30% yield. 
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Scheme 2.2. Synthesis of the monomer 9,9-bis-(3-bromo-propyl)-2,7-divinyl-9H-
fluorene (M2) (inset image represents the reaction medium under 366 nm UV light) via 
Stille Coupling. 
The polymerization reactions in this work go through step-growth mechanism in which 
bifunctional or multifunctional monomers react to form first dimers, then trimers, then 
longer oligomers and eventually long chain polymers. Actually,  stoichiometry of 
functional monomers is crucial to get longer polymers. Therefore, the purification of 
monomers becomes very important to achieve longer chain polymers. As usual, the 
monomer M2 was purified through column chromatography and checked with thin layer 
chromatography (TLC) under UV light. At the end of column chromatography, four 
fractions labelled as M2-A, M2-B, M2-C and M2-D were collected respectively. As 
shown in Figure 2.3., the one spot on TLC plate under 254 nm UV light belongs to the 
desired di-substituted monomer, however an additional spot appeared when switched to 
366 nm UV light. Although, there are two spots under 366 nm UV light, the below one 
overlaps with the one under 254 nm light. Therefore, above spot belongs to a different 
molecule whose structure is very close to the monomer M2. These four fractions were 
characterized by 
1
H-NMR spectroscopy and TOF LC/MS, then it was found out that 
this second spot belongs to  mono-substituted monomer. The amount of this molecule 
decreases in the fractions M2-A to M2-C, then it finishes in M2-D that consists of only 
the desired monomer M2.  
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Figure 2.3. Cartoon representation of  the spots on TLC plate under 254 and 366 nm 
UV light for four fractions (M2-A/B/C/D) of 9,9-bis-(3-bromo-propyl)-2,7-divinyl-9H-
fluorene (M2). 
The comparative 
1
H-NMR spectra of four fractions is shown in Figure 2.4. The 
1
H-
NMR spectra are very similar to each other except the case in the aromatic region. 
Although there are small differences in the intensities of the peaks for vinyl and alkyl 
protons, the easily noticable difference is observed at aromatic region. The intensities of 
the peaks around 7.5-7.6 ppm gradually decrease through the fraction M2-A to M2-C, 
then almost dissappear in the spectrum of M2-D. The aromatic protons of fluorene and 
benzothiadiazole segments are observed as multiplets at 7.4-7.7 ppm. The peaks as 
multiplets at 6.8, 5.8 and 5.3 ppm are referred to the vinyl protons. The triplet at 3.18 
ppm exhibits the presence of deshielded -CH2 protons due to the presence of 
electronegative bromine in close proximity. Moreover, the triplet at 2.2 ppm for the 
protons of methylene near to bromine group and the multiplet at 1.1 ppm for the protons 
of methylene next to aromatic ring. 
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Figure 2.4. 
1
H-NMR (400 MHz, CDCl3, 25 
o
C) spectra of four fractions (M2-A/B/C/D) 
of 9,9-bis-(3-bromo-propyl)-2,7-divinyl-9H-fluorene (M2) *Denotes for impurities in 
the solvent. 
TOF LC/MS results shown in Figure 2.5 confirm the arguments in  
1
H-NMR 
characterization. . The intensities of the peaks corresponding the mono-subtituted 
monomer gradually decrease through the fraction M2-A to M2-C, then almost 
dissappear in M2-D. As a result, M2-D consists of only the desired monomer M2 and 
has been used for the polymerization reactions. 
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Figure 2.5. TOF LC/MS results of four fractions (M2-A/B/C/D) of 9,9-bis-(3-bromo-
propyl)-2,7-divinyl-9H-fluorene (M2) (y-axis scale is same for all). 
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2.1.3. Synthesis and Characterization of 2,7-dibromo-9,9-bis-(propenyl)-9H-
fluorene (M3) 
2,7-dibromo-9,9-bis(propenyl)-9H-fluorene (M3) was previously synthesized
103
 from 
2,7-dibromofluorene and allybromide according to Scheme 2.3. As same with the 
procedure of the monomer M1, 50% (w/w) NaOH solution provided very strong basic 
condition utilizing the abstraction of weakly acidic C9-H. Then, excess allybromide 
reacted with the resulting anion by adding to 9-position through nucleophilic 
substitution reaction. After the isolation and purification of the product, the monomer 
M3 was obtained with 89% yield.  
1
H-NMR (400 MHz, CDCl3, δ ppm): 7.52 (m, 6H), 5.21 (m, 2H), 4.89 (m, 4H), 2.68 (t, 
4H). 
 
Scheme 2.3. Synthesis of the monomer 2,7-dibromo-9,9-bis-(propenyl)-9H-fluorene 
(M3). 
2.2. Synthesis and Characterization of Polymers 
2.2.1. Synthesis and Characterization of Poly[(9,9- bis{propenyl}fluorenyl-2,7-
diyl))-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PPFBT) 
The polymer PPFBT was previously synthesized
103
 using Suzuki coupling reaction of 2, 
7-dibromo-9,9-bis-(propenyl)-9H-fluorene  and 1,2,3-benzothiadiazole-4,7-bis (boronic 
acid pinocol ester) as shown in Scheme 2.4. The polymer was purified by the 
precipitation of the polymer solution in THF into cold methanol to provide orange 
powder in 60% yield. 
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Scheme 2.4. Synthesis of the polymer poly[(9,9- bis{propenyl}fluorenyl-2,7-diyl))-co-
(1,4-benzo-{2,1,3}-thiodiazole)] (PPFBT) via Suzuki coupling. 
PPFBT was characterized by 
1
H-NMR, UV-Vis, Fluorescence and FT-IR 
spectroscopies.  
1
H-NMR spectrum of PPFBT is shown in Figure 2.6. Signals observed 
at around 7.8-8.2 ppm as multiplets are for the aromatic protons of fluorene and 
benzothiodiazole units. The multiplets at 5.5 ppm and 4.8-5.1 ppm are assigned to the 
alkenyl protons of allyl group and the signal at 2.8 ppm is due to the –CH2 protons of 
allyl group.  
 
Figure 2.6. 
1
H-NMR (400 MHz, CDCl3, 25 
o
C) spectrum of poly[(9,9- 
bis{propenyl}fluorenyl-2,7-diyl))-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PPFBT). 
FT-IR spectrum of the polymer PPFBT is shown in Figure 2.7.  FT-IR spectrum shows 
a peak at 3074 cm
-1
 for Ph-H stretching and characteristic peak of R-CH=CH2 was 
observed at 910 cm
-1 
due to out- of - plane C-H bendings. Peaks are observed at 1461 
cm
-1
, 2918 cm
-1
 and 1609 cm
-1
 for –C=N stretching in benzothiadiazole moiety and 
aliphatic –C-H stretching, C=C stretching of benzene rings, respectively. 
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Figure 2.7. FT-IR spectrum of poly[(9,9- bis{propenyl}fluorenyl-2,7-diyl))-co-(1,4-
benzo-{2,1,3}-thiodiazole)] (PPFBT). 
UV-Vis absorption and fluorescence emission properties of the polymer PPFBT in THF 
are shown in the spectra in Figure 2.8. The maximums of absorption band at 317 and 
447 nm and the maximum of fluorescence emission band at 537 nm were observed that 
it is in the range of green in the visible light. 
 
Figure 2.8. UV-vis absorption and fluorescence emission spectra of poly[(9,9- 
bis{propenyl}fluorenyl-2,7-diyl))-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PPFBT) in THF 
(λex=447 nm). 
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2.2.2. Synthesis and Characterization of Poly[(9,9-bis{3-bromo-propyl}fluorenyl-
2,7-divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PBPFVBT) and Poly[(9,9-bis{3-
azido-propyl}fluorenyl-2,7-divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] 
(PAPFVBT) 
The polymer, poly[(9,9-bis{3-bromo-propyl}fluorenyl-2,7-divinylene)-co-(1,4-benzo-
{2,1,3}-thiodiazole)] (PBPFVBT) was synthesized through Heck coupling 
polymerization shown in Scheme 2.5. In fact, Heck polymerization needs a reaction 
medium with very basic organic solvent like triethylamine (TEA). However, the 
reaction temperature is very high (100
 o
C) that causes to form insoluble byproducts by 
the reaction of the monomers with alkyl bromides with basic organic solvent. Therefore,  
K2CO3 was used instead of such basic organic solvent to provide basic reaction 
medium. By incorporating vinyl bonds within the fluorene and benzothiadiazole 
segments, red-shift in the fluorescence was obtained via Heck polymerization that 
PBPFVBT was synthesized by heating the mixture of 9,9-bis-(3-bromo-propyl)-2,7-
divinyl-9H-fluorene (M2) and 4,7-dibromo-2,1,3-benzothiadiazole in 
K2CO3/water/DMF using Pd(OAc)2/ PPh3 as catalyst at 100 
o
C for 14 h. The polymer 
was purified by the precipitation of the polymer solution in THF into cold methanol to 
provide red powder in 52% yield. 
 
Scheme 2.5. Synthesis of the polymer poly[(9,9-bis{3-bromo-propyl}fluorenyl-2,7-
divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PBPFVBT) via Heck coupling. 
PBPFVBT was characterized by 
1
H-NMR, UV-Vis, Fluorescence and FT-IR 
spectroscopies. 
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1
H-NMR spectra of PBPFVBT are shown in Figure 2.6. The polymer is soluble in 
CDCl3 and DMSO-d6, so the spectra in both solvents are given. Some shifts are 
observed due to solvent effect.  The multiplet at 7.5-8.2 ppm are accounting for the 
aromatic protons of both fluorene and benzothiadiazole segments. The triplet at 3.4 ppm 
reveals the presence of deshielded -CH2 protons due to the presence of electronegative 
bromine in close proximity. The weak peaks as multiplets at 6.8, 5.8 and 5.2 ppm are 
referred to the resonance of vinyl protons of fluorenylvinylene end groups of 
PBPFVBT. The polymer is in trans configuration since there is no peak at around 6.5 
ppm correspondig to resonance peak of cis vinyl protons. For biosensor applications, it 
is beneficial to have trans configuration since in additon to providing electron 
delocalization along the backbone, backbone planarization  is achieved that result in red 
shift of absorption and emission maxima compared to cis configuration
23
. Furthermore, 
there are multiplets observed at 2.1 and 0.9 ppm for the other protons on the alkyl chain 
constituting the side chain. 
 
Figure 2.9. 
1
H-NMR (400 MHz, CDCl3{above} and DMSO-d6{below}, 25 
o
C) spectra 
of poly[(9,9-bis{3-bromo-propyl}fluorenyl-2,7-divinylene)-co-(1,4-benzo-{2,1,3}-
thiodiazole)] (PBPFVBT). 
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When the polymer PBPFVBT is dissolved in various solvents having different 
polarities, a change in color is observed that indicates it solvatochromic property shown 
in Figure 2.10. PBPFVBT was dissolved in THF, CHCl3, DMF and DMSO in order of 
increasing polarity that results in red shift. Actually, the polymer has different polarity 
when it is in ground or excited states, so the stabilization of these states is different 
when the solvent polarity is changing
104
. Therefore, a change in the energy gap between 
ground and excited states is observed, such that the gap is decreasing when the solvent 
polarity is increased. 
 
Figure 2.10. Solvatochromic property of poly[(9,9-bis{3-bromo-propyl}fluorenyl-2,7-
divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PBPFVBT). 
To eliminate toxic effects for cell culture studies, bromine group of PBPFVBT 
converted into azide group resulting in poly[(9,9-bis{3-azido-propyl}fluorenyl-2,7-
divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PAPFVBT). PAPFVBT was 
synthesized in 83% yield by heating the mixture of PBPFVBT and NaN3 in DMF using 
at 60 
o
C for 24 h via nucleophilic substitution reaction. 
 
Scheme 2.6. Synthesis of the polymer poly[(9,9-bis{3-azido-propyl}fluorenyl-2,7-
divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PAPFVBT). 
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PAPFVBT was characterized by UV-Vis, Fluorescence and FT-IR spectroscopies. In 
Figure 2.11., the FT-IR spectra of PBPFVBT and PAPFVBT are depicted which they 
are very similar to each other except for the stretching band of azide at 2020 cm
-1
 
confirming the successful functionalization. The aromatic C=C bonds are observed at 
1620 cm
-1
, while a strong peak at 1431 cm
-1
 corresponds to the C-C stretching of the 
aromatic fluorene backbone of the polymer.  The presence of aliphatic C-H stretching is 
indicated by the peak at 2961 cm
-1
. C-Br stretching is observed at 822 cm
-1
. Although 
NMR spectroscopy is most useful for determining the structure of molecules that 
provides much more information than F-TIR, FT-IR is very useful to identify functional 
groups. That’s why azide functionalization was proved by FT-IR. 
  
Figure 2.11. FT-IR (KBr pellets) spectra of poly[(9,9-bis{3-bromo-propyl}fluorenyl-
2,7-divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PBPFVBT) and poly[(9,9-bis{3-
azido-propyl}fluorenyl-2,7-divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] 
(PAPFVBT). 
Optical characterization of the polymers PBPFVBT and PAPFVBT was performed bu 
UV-Vis and fluorescence spectroscopies. For both polymers, there is a broad absorption 
band having maxima at 340 and 420 nm. However, 30 nm blue-shift is observed in the 
emission maximum of azide funtionalized polymer compared to the emission maximum 
(575 nm) of the polymer with bromine group. 
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Figure 2.12. UV-vis absorption and fluorescence emission spectra of poly[(9,9-bis{3-
bromo-propyl}fluorenyl-2,7-divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] 
(PBPFVBT) and poly[(9,9-bis{3-azido-propyl}fluorenyl-2,7-divinylene)-co-(1,4-
benzo-{2,1,3}-thiodiazole)] (PAPFVBT) (λex=420 nm). 
2.3. Synthesis and Characterization of Blank and Drug Loaded Water 
Dispersible Conjugated Polymer Nanoparticles (CPNs) 
Blank and drug loaded conjugated polymer nanoparticles were prepared through a 
simple reprecipitation method in which the polymer or the mixture of drug and polymer 
solution in THF (a good solvent) was injected into a large excess of water (a poor 
solvent) while sonicating. After the removal of THF under reduced pressure, stable 
nanoparticles in spherical shape were obtained. The main driving forces for the 
encapsulation of drug by the polymer to form drug-loaded nanoparticles were probably 
the hydrophobic effect and π-π interaction between aromatic polymer backbone and 
aromatic rings of drug. 
The characterization of nanoparticles was done by the help of DLS and Zeta Potential 
measurements to determine their sizes and stability, UV-vis and Fluorescence 
Spectroscopies to investigate their optical properties, SEM, TEM and AFM to assign 
their morphology. 
 
 
38 
 
2.3.1. Synthesis and Characterization of Poly[(9,9- bis{propenyl}fluorenyl-2,7-
diyl))-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PPFBT) Nanoparticles 
Firstly, the polymer PPFBT was dissolved in THF. The resulting solution was sonicated 
for 30 min and then injected rapidly into autoclaved double distilled water . It was 
stirred with sonication for further 30 min. THF was removed under reduced pressure. 
The resulting nanoparticle solution was concentrated by evaporating its water under 
reduced pressure. The size of nanoparticles and the zeta potential values were measured 
as 21.49 nm and -37.6  mV, shown in Figure 2.13. 
 
Figure 2.13. (a) Size distrubiton histogram from DLS measurement and (b) zeta 
potential measurement of PPFBT Nanoparticles. 
Optical characterization of PPFBT nanoparticles was investigated with UV-Vis and 
fluorescence spectroscopies and compared with the polymer in THF and in solid state 
(Figure 2.14). Maximum absorption peaks were observed at 317, 447 nm for polymer in 
THF; these are almost the same for nanoparticle dispersion in water but approximately 
10 and 25 nm red shifted for the film of the polymer. However, when nanoparticle 
dispersion in water were excited with 447 nm light, green-yellow emission band at 550 
nm was observed which was 13 nm red shifted compared to the emission band of the 
polymer in THF. If the emission wavelengths of nanoparticles in water compared with 
the emission wavelength of the polymer film, it can be seen that only there is 8 nm 
difference between them (550 nm for nanoparticle dispersion in water and 558 nm for 
the polymer film) indicating that optical properties of nanoparticles in water resembles 
to polymer’s solid state properties. The quantum yield of the polymer in THF is 70%, 
while it becomes 26% when nanoparticle formation in water
103
.  
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Figure 2.14. UV–vis absorption and fluorescence emission spectra of PPFBT in THF 
(λexc.= 447 nm), as film (λexc.= 472 nm) and as dispersions of the nanoparticles in water 
(λexc.= 447 nm). 
The red shift of emission maximum for CPNs compared to polymer in THF shows  the 
aggregation of polymer chains upon nanoparticle formation in water. As a result of 
aggregation, the overlap of π-orbitals increases, then followed by π-electrons 
delocalization across the chains. The lower band gaps, observed by red shift, are the 
sign of this delocalization
41,50-52
. Similarly, the red shift of emission maximum for the 
solid state of polymer is the result of tight packing of polymer chains
44
. 
2.3.1.1. Cell Viability of PPFBT Nanoparticles 
Dose dependent in vitro cytotoxicity test of the blank PPFBT nanoparticles (~22 nm) 
against Huh7 cells were performed through SRB assay and the results were plotted as in 
Figure 2.15. The cytotoxicity assay of the blank nanoparticles indicates that they are not 
toxic to the Huh7 cells up to 25 µM at the end of 72 h. Therefore, their convenience for 
further studies on cell imaging and the drug delivery is proven. 
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Figure 2.15. Percent cell viability results of PPFBT nanoparticles having 
concentrations of 25, 12.5, 6.25, 3.125, 1.5625 μM after 72 h incubation. 
2.3.2. Synthesis and Characterization Drug Loaded PPFBT Nanoparticles 
2.3.2.1. Determination of Loading Efficiency: Synthesis and 
Characterization of Anthracene(ANT)-Loaded PPFBT Nanoparticles 
Anthracene was chosen for having aromatic rings like Camptothecin in order to be a 
positive control in the determination of drug loading efficiency. PPFBT and ANT were 
dissolved in THF and the resulting solution was injected into rapidly stirring water. 
After the removal of THF, ANT-loaded nanoparticles were obtained. In order to 
determine the optimum loading capacity of nanoparticles, the ratios of PPFBT to ANT 
(w:w) 25:1 and 5:1 were used during the nanoparticle preparation. In each case, after 
the nanoparticle formation, the dispersion was filtered through to remove the 
unencapsulated ANT. The size of nanoparticles and the zeta potential values were 
measured as 21.00 nm and -38.2  mV for the one with the ratio of 25:1, as 21.52 nm and 
-41.9  mV for the one with the ratio of 5:1, shown in Figure 2.16. 
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Figure 2.16. Size distribution histograms from DLS measurements of (ANT)-loaded 
PPFBT nanoparticles having the ratios PPFBT to ANT (w:w) 25:1 (a) and 5:1 (c) ; Zeta 
potential measurements of (ANT)-loaded PPFBT nanoparticles having the ratios PPFBT 
to ANT (w:w) 25:1 (b) and 5:1 (d). 
The synthesis of anthracene (ANT)-loaded PPFBT nanoparticles and the determination 
of the optimum loading efficiency of the nanoparticles are illustrated in Figure 2.17. In 
the first step, UV-vis and PL spectra of  PPFBT to ANT in various ratios dissolved in 
THF were recorded. These spectra were compared with the spectra of only ANT in THF 
and only PPFBT in THF. Some parts of the absorption peaks of ANT and PPFBT 
overlap, so the presence of ANT in the mixtures can be seen as shoulders on the peaks 
of PPFBT. The intensity of the shoulders increases when the amount of ANT increases 
(such as the one with the ratio of 5:1). However, the emission peaks of each ANT and 
PPFBT can be easily distinguishable in the mixtures. As expected, the intensity of ANT 
decreases when its portion in the mixture decreases. In the second step, the solutions 
prepared in the first step were injected into water. Then, THF was removed and the 
dispersion was filtered through filter papers. The residue on the filter paper was 
dissolved in THF and analyzed via UV-vis and fluorescence spectroscopy by following 
the absorption and emission maxima of ANT. As it can be seen from both of the 
absorption and PL spectra, the residue of the dispersion with 5:1 ratio consists of only 
unencapsulated ANT while all of the ANT is encapsulated in the one with 25:1 ratio.  
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Figure 2.17. The cartoon representation of the synthesis of anthracene (ANT)-loaded 
PPFBT nanoparticles and the determination of the optimum loading efficiency of the 
nanoparticles. UV-Vis absorption and fluorescence emission spectra of PPFBT to ANT 
in various ratios dissolved in THF and the precipitate on the filter papers dissolved in 
THF (λexc.= 350 nm). 
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Moreover, the amount of unencapsulated ANT was determined via the calculation of the 
area under fluorescence emission curves. In Figure 2.18, firstly UV-Vis absorption and 
fluorescence emission spectra of ANT with increasing its amount were recorded, then a 
calibration curve called fit curve was obtained from the area of fluorescence emission 
curves (between 370 and 462 nm) versus the amount of ANT. The absorption curves 
could not be used for this purpose because of overlapping of the absorption peaks of 
ANT and PPFBT. Secondly, the area under the emission curves of the residue on the 
filter papers were calculated and then the resulting values were put in the linear 
equation of fit curve to find out the amount of unencapsulated ANT, so then the 
encapsulated portion. The mole of encapsulated ANT to the mole of polymer was found 
as 8% and 4% for the dispersions with 5:1 and 25:1 ratios, respectively. Although the 
capacity of encapsulation is up to 8%, it is guaranteed to encapsulate all by preparing 
the dispersions with the quantities resulting 4%. Finally, the loading efficiency was 
determined by the weight percent of encapsulated ANT to initally added ANT through 
nanoparticle formation so it was determined to be 100% when PPFBT to ANT ratio was 
25:1.  
 
Figure 2.18. UV-Vis absorption and fluorescence emission spectra of Anthracene 
(ANT) while increasing its amount (λex=350 nm). The below fit curve represents the 
area of fluorescence emission curves (between 370 and 462 nm) vs. the amount of 
ANT. 
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2.3.2.2. Determination of Drug Loading Efficiency: Synthesis and 
Characterization of Camptothecin (CPT)-Loaded PPFBT Nanoparticles 
A similar approach to the work on ANT loading was followed to determine the drug 
loading efficiency by encapsulating CPT. PPFBT and CPT were dissolved in THF and 
the resulting solution was injected into rapidly stirring water. After the removal of THF, 
drug-loaded nanoparticles were obtained. This time, the ratios of PPFBT to CPT (w:w) 
25:1, 15:1 and 10:1 were used during the nanoparticle preparation. In Figure 2.19,  the 
size and the zeta potential values of nanoparticles were measured as 24.69, 23.33, 23.78 
nm and -33.1, -46.19/-18.0, -39.7/-59.1 for the ones with the ratio of 25:1, 15:1 and 
10:1, respectively. 
 
Figure 2.19. Size distribution histograms from DLS measurements of  (CPT)-loaded 
PPFBT nanoparticles having the ratios PPFBT to CPT (w:w) 25:1 (a) 15:1 (c) and 10:1 
(e) ; Zeta potential measurements of (CPT)-loaded PPFBT nanoparticles having the 
ratios PPFBT to CPT (w:w) 25:1 (b) 15:1 (d) and 10:1 (f). 
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Figure 2.20.  The cartoon representation of the synthesis of camptothecine (CPT)-
loaded PPFBT nanoparticles and the determination of the optimum drug loading 
efficiency of the nanoparticles. UV-Vis absorption and fluorescence emission spectra of 
PPFBT to CPT in various ratios dissolved in THF and the precipitate on the filter papers 
dissolved in THF (λexc.= 365 nm). 
The synthesis of CPT-loaded PPFBT nanoparticles and the determination of the 
optimum loading efficiency of the nanoparticles are illustrated in Figure 2.20. In the 
first step, UV-vis and PL spectra of  PPFBT to CPT in various ratios dissolved in THF 
were recorded. These spectra were compared with the spectra of only CPT in THF and 
only PPFBT in THF. Like in the case of ANT, some parts of the absorption peaks of 
CPT and PPFBT overlap , so the presence of CPT in the mixtures can be seen as 
shoulders on the peaks of PPFBT. The intensity of the shoulders increases when the 
amount of CPT increases through 25:1 to 10:1 ratios. Although, there is small overlap in 
the end of CPT emission peak and the start of PPFBT emission peak, the emission 
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bands of each one can be easily distinguishable in the mixtures. As expected, the 
intensity increases when the amount of CPT increases through 25:1 to 10:1 ratios. In the 
second step, the solutions prepared in the first step were injected into water. Then, THF 
was removed and the dispersion was filtered through filter papers. The residue on the 
filter paper was dissolved in THF and analyzed via UV-vis and fluorescence 
spectroscopy by following the absorption and emission maxima of CPT. As it can be 
seen from the PL spectra, all of the drug was encapsulated in the dispersion with 25:1 
ratio.  
In Figure 2.21, UV-Vis absorption and fluorescence emission spectra of CPT with 
increasing its amount are recorded, then fit curve was obtained from the area of 
fluorescence emission curves versus the amount of CPT. Secondly, the area under the 
emission curves of the residue on the filter papers were calculated and then the resulting 
values were put in the linear equation of fit curve to find out the amount of 
unencapsulated drug, so then the encapsulated portion.  The mole of encapsulated CPT 
to the mole of polymer was found as 11%, 7% and 4% for the dispersions with 10:1, 
15:1 and 25:1 ratios, respectively. Actually, it is highly possible to encapsulate all of the 
drug by preparing the dispersions with the quantities resulting 4%.  
 
Figure 2.21. UV-Vis absorption and fluorescence emission spectra of Camptothecin 
(CPT) while increasing its amount (λex=365 nm).  
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The CPT loading efficiency in the nanoparticles was determined to be 100% when a 
polymer to drug ratio of 25:1 was used. This was also supported by an additional 
experiment in which the water of the CPT-loaded nanoparticles after filtration was 
evaporated off and the remaining residue was dissolved in DMSO-d6 and analyzed by 
1
H-NMR spectroscopy shown in Figure 2.22. As the main difference between these 
spectra, the CPT peaks at positions (h), (i), (j), (k) and (l) can be clearly observed in the 
spectrum of drug loaded nanoparticle dispersion (above). 
 
Figure 2.22. 
1
H-NMR (400 MHz, DMSO-d6, 25 °C) spectra of the remaining residue of 
PPFBT nanoparticles  and filtrated CPT-loaded PPFBT nanoparticles after evaporation 
off  (*denotes for impurities). 
Optical characterization of the nanoparticles with drug to polymer ratio of 25:1 was 
done by UV-Vis and fluorescence emission spectroscopies. In Figure 2.23, the 
absorption and emission spectra of nanoparticle dispersion in water were compared with 
the spectra of only CPT in water and only blank nanoparticles in water. Aqueous CPT 
has absorption maximum at 365 nm, and blank nanoparticles has absorption maxima at 
317 and 447 nm (Figure 2.23.(a)). When they are excited at 447 nm (Figure 2.23 (c)), 
the emission maxima of the nanoparticle dispersion is observed at around 537 nm, 
however the emission peak of CPT could not be observed. When they are excited at 365 
nm (Figure 2.23 (b)), the emission maxima of  CPT is observed at around 426 nm, but 
this time the emission peak of the nanoparticle dispersion dissappears. 
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Figure 2.23. UV–vis absorption and fluorescence emission spectra of CPT-loaded 
PPFBT nanoparticles , PPFBT nanoparticles  and CPT as dispersions in water (b) λexc.= 
365 nm (c) λexc.= 447 nm. 
2.3.2.3. Synthesis and Characterization of Camptothecin (CPT)-Loaded 
PPFBT Nanoparticles as a Drug Carrier and a Fluorescent Probe for Cell Imaging 
After the CPT loading efficiency in the nanoparticles was determined to be 100% when 
a polymer to drug ratio of 25:1 was used, the synthetic conditions were kept constant for 
drug loaded nanoparticles that would be used for cell studies. The syntheses of blank 
and CPT-loaded nanoparticles were repeated three times. Their size were determined by 
dynamic light scattering (DLS) measurements (Figure 2.24) and the averages of three 
different DLS measurements were calculated as 25.50±0.76 nm for blank nanoparticles 
and 24.38±1.37 nm for drug loaded nanoparticles by dynamic light scattering 
measurements (Table 1). The morphologies of blank nanoparticles and CPT loaded 
nanoparticles were revealed by TEM and AFM (Figure 2.26) imaging techniques. The 
zeta potential values were measured as -51.17±2.16 and -29.80±6.52 mV for blank 
nanoparticles and -40.70±4.82 mV for CPT loaded nanoparticles (Figure 2.25 and Table 
1), which indicate the formation of stable nanoparticle dispersion caused by the 
repulsion between the nanoparticles. As can be seen from the DLS measurements, no 
significant changes were observed in their diameters, indicating that the structural 
integrity of nanoparticles were not affected when they are loaded with drug.   
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Table 1. Size and Zeta potential values of PPFBT nanoparticles and CPT-loaded 
PPFBT nanoparticles. 
 
 
Figure 2.24. Size distribution histograms from DLS measurements of PPFBT 
nanoparticles and CPT-loaded PPFBT nanoparticles. 
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Figure 2.25. Zeta potential measurements of PPFBT nanoparticles and CPT-loaded 
PPFBT nanoparticles. 
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Figure 2.26. TEM images of PPFBT nanoparticles (a) and CPT-loaded PPFBT 
nanoparticles (b). AFM images of PPFBT nanoparticles (c) and CPT-loaded PPFBT 
nanoparticles (d). 
Fluorescence microscope images of CPT-loaded PPFBT nanoparticles and Huh7 cells 
incubated with blank and (CPT)-loaded PPFBT nanoparticles are shown in Figure 2.27. 
The bright green CPN emission is the evidence for the efficent cellular uptake of these 
small nanoparticles, even for very short incubation time (24 h).  These nanoparticles 
were accumulated in cytoplasm and around the nucleus.   
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Figure 2.27. Fluorescence microscope images (40x) of CPT-loaded PPFBT 
nanoparticles having concentrations of  PPFBT as 0.04 mg / mL (a) and 0.75 mg / mL 
(b);  Huh7 cells incubated with PPFBT nanoparticles ( [PPFBT]=25 μM) (c) and (CPT)-
loaded PPFBT nanoparticles ( [PPFBT]=6.25 μM, [CPT]=0.25 μM) (d) after 24 h. 
Time and dose dependent in vitro cytotoxicity tests of the blank CPNs, CPT loaded 
CPNs and free CPT against Huh7 cells were performed through SRB assay and the 
results were plotted as in Figure 2.28 a and b. In this experimental set-up, free CPT was 
used as a positive control and DMSO and blank CPNs were used as negative controls to 
CPT loaded CPNs. At the end of 48 h, the IC50 of free CPT and CPT loaded CPNs were 
calculated to be 0.9 µM and 0.1 µM respectively, corresponding to that CPT loaded 
CPNs are 9 times more effective than free CPT.  However, at the end of 72 h, the IC50 
of free CPT and CPT-loaded CPNs decreased to 0.1 µM and 0.008 µM, respectively. In 
this case, CPT-loaded CPNs are 12.5 times more effective than free CPT in inducing the 
apoptosis of Huh7 cells. Although the free drug (CPT) reaches IC50 of 0.1 µM after 72 
h, it is possible to achieve this value with CPT-loaded CPNs at the end of 48 h.  
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Figure 2.28. Percent  cell death with CPT-loaded PPFBT Nps, PPFBT Nps, CPT and 
DMSO. Huh7 cells were inoculated in 24-well plates. All molecules and their DMSO 
controls were administered to the cells in triplicates with five different concentrations: 
1, 0.5, 0.25, 0.125, and 0.0625 μM. After 48h (a) and 72h (b) of incubation, SRB assays 
were generated and the cell death percentages were calculated in comparison with 
DMSO-treated wells. Huh7 cells plated concomitantly on coverslips and treated 
identically were Hoechst 33258 stained and examined under a fluorescence microscope 
(40x) only for labelled (dashed oval) conditions (c and d for a) and (e and f for b). 
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SRB assay results clearly confirm that CPT-loaded nanoparticles have been taken up by 
the cells and unloaded their payload very efficiently. With this delivery system, even 
very low dose of CPT is found to be sufficient to induce the apoptosis of Huh7 cells; 
this is certainly a very desirable goal in the chemotherapy. The cellular uptake of the 
blank CPNs and CPT-loaded CPNs were analyzed by fluorescence microscope (using 
Huh7 cells) in Figure 2.28. only for dashed oval conditions. More microscope images 
on dose dependent study of DMSO-only, CPT-only, Np-only and CPT-loaded Nps 
treated cells are given in Figure 2.29, Figure 2.30 and Figure 2.31. These nanoparticles 
were accumulated in the cytoplasm and around the nucleus suggesting that the uptake 
might be achieved via endocytosis.  Especially, CPT-loaded CPNs seem to be densely 
populated around the destroyed nucleus as well as within the nucleus when it was 
fragmented through apoptosis.  
 
Figure 2.29. Huh7 cells plated concomitantly on coverslips and treated identically were 
Hoechst 33258 stained and examined under a fluorescence microscope (40x) after 72 h 
incubation with DMSO-only (a-d) and 0.5 μM (e) 0.25 μM (f) 0.125 μM (g) 0.0625 μM 
(h) CPT-only which were used as controls in serial dilutions. 
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Figure 2.30. Huh7 cells plated concomitantly on coverslips and treated identically were 
Hoechst 33258 stained and examined under a fluorescence microscope (40x) after 72 h 
incubation with 12.5 μM (a) 6.25 μM (b) 3.125 μM (c) 1.5625 μM (d) PPFBT 
nanoparticles.  
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Figure 2.31. Huh7 cells plated concomitantly on coverslips and treated identically were 
Hoechst 33258 stained and examined under a fluorescence microscope (40x) after 72 h 
incubation with [CPT]=0.5 μM, [PPFBT]=12.5 μM (a) [CPT]=0.25 μM, [PPFBT]=6.25 
μM (b) [CPT]=0.125 μM, [PPFBT]=3.125 μM (c) [CPT]=0.0625 μM, [PPFBT]=1.5625 
μM (d) CPT-loaded PPFBT nanoparticles.  
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The high efficacy of this approach can be attributed to a number of factors. Amongst 
them, the drug-loaded nanoparticles have potential to avoid multidrug resistance 
mechanisms (MRMs) when they enter cells via endocytosis
105
. MRMs operate through 
the transmembrane drug efflux pumps effect involving cell-surface proteins such as 
glycoproteins which can prevent small drugs to enter the cells. CPT is a water insoluble 
drug molecule which dissolves in organic solvents (e.g. DMSO) or in the acidified 
water. None of them are desirable because for the former, DMSO has toxic effects to 
the cells and, for the latter, CPT molecules are hydrolyzed in the acidic aqueous media, 
and in turn, this causes their inhibitory activities to be diminished. However, the 
encapsulation renders the water solubility of CPT molecules and provides stability to 
preserve their full activity. 
2.3.3. Synthesis and Characterization of Poly[(9,9-bis{3-azido-propyl}fluorenyl-
2,7-divinylene)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PAPFVBT) Nanoparticles 
Firstly, the polymer PAPFVBT was dissolved in THF. The resulting solution was 
sonicated for 30 min and then injected rapidly into autoclaved double distilled water . It 
was stirred with sonication for further 30 min. THF was removed under reduced 
pressure. The resulting nanoparticle solution was concentrated by evaporating its water 
under reduced pressure. The size of nanoparticles and the zeta potential values were 
measured as 146.5 nm and -35  mV, shown in Figure 2.32. 
 
Figure 2.32. (a) Size distribution histogram from DLS measurement and (b) zeta 
potential measurement of PAPFVBT Nanoparticles. 
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Optical characterization of PAPFVBT nanoparticles was investigated with UV-Vis and 
fluorescence spectroscopies and compared with the polymer in THF and in solid state 
(Figure 2.33). For all three cases, there is a broad absorption band having maxima at 
340 and 420 nm. When the polymer in THF was excited with 420 nm light, the 
emission maximum at 545 nm was observed. When nanoparticle dispersion in water 
were excited with 420 nm light, the emission maximum at 608 nm was observed which 
was 63 nm red shifted compared to the emission band of the polymer in THF. If the 
emission maximum of nanoparticles in water compared with the emission maximum of 
the polymer film (617 nm), it can be seen that only 9 nm red shift was observed for the 
polymer film indicating that optical properties of nanoparticles in water resembles to 
polymer’s solid state properties. 
 
Figure 2.33. UV–vis absorption and fluorescence emission spectra of PAPFVBT in 
THF, as film and as dispersions of the nanoparticles in water (λexc.= 420 nm). Inset 
images represent real images of these three states under 366 nm UV light. 
2.3.3.1. Cell Viability of PAPFVBT Nanoparticles 
Through SRB assay, dose dependent in vitro cytotoxicity test of the blank PAPFVBT 
nanoparticles (~147 nm) against Huh7 cells were performed. The results were plotted as 
in Figure 2.34. and indicate that they are not toxic to the Huh7 cells up to 16 µM at the 
end of 72 h. Their higher percent viability results can be explained in a way that red 
emitting conjugated polymers have lower energy that make them better for biomedical 
applications without tissue damage. As a result, their convenience for further studies on 
cell imaging and the drug delivery was demonstrated.  
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Figure 2.34. Percent cell viability results of PAPFVBT nanoparticles having 
concentrations of 16, 8, 4, 2, 1 μM after 72 h incubation. 
2.3.4. Synthesis and Characterization of Camptothecin (CPT) - Loaded 
PAPFVBT Nanoparticles as a Drug Carrier 
The synthetic conditions, in which the polymer to drug ratio was 25:1, were kept 
constant for drug loaded nanoparticles that would be used for cell studies. The size of 
the blank and CPT-loaded nanoparticles were determined by dynamic light scattering 
(DLS) measurements (Figure 2.35 a, b) and as 146.5 nm for blank nanoparticles and 
152.2 nm for drug loaded nanoparticles. The morphologies of blank nanoparticles and 
CPT loaded nanoparticles were revealed by SEM (Figure 2.35 c, d) imaging technique. 
The zeta potential values were measured as -35.0 mV for blank nanoparticles and -
42.0/-16.8 mV for CPT loaded nanoparticles (Figure 2.35 e, f), which indicate the 
formation of stable nanoparticle dispersion caused by the repulsion between the 
nanoparticles. As can be seen from the DLS measurements, no significant changes were 
observed in their diameters, indicating that the structural integrity of nanoparticles were 
not affected when they are loaded with drug.   
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Figure 2.35. Size distribution histograms from DLS measurements of PPFBT 
nanoparticles (a) and CPT-loaded PPFBT nanoparticles (b); SEM images of PPFBT 
nanoparticles (c) and CPT-loaded PPFBT nanoparticles (d); Zeta potential 
measurements of PPFBT nanoparticles (e) and CPT-loaded PPFBT nanoparticles (f) 
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In Figure 2.36, dose dependent in vitro cytotoxicity tests of the blank CPNs, CPT 
loaded CPNs and free CPT against Huh7 cells were performed through SRB assay. Free 
CPT was used as a positive control and DMSO and blank CPNs were used as negative 
controls to CPT loaded CPNs. SRB test system is based on quantitative staining of 
cellular protein by SRB dye. Therefore, more purple color indicates more live cells like 
in the regions of I, IV and V. As expected, the regions of II and III belonging to the 
cells treated with CPT-loaded nanoparticles and free CPT are almost clear that this 
anticancer drug kills these cancer cells. 
 
Figure 2.36. The image of 96-well plate with SRB dye after 72 h incubation. 
The SRB results were plotted as in Figure 2.37. At the end of 72 h, IC50 of free CPT and 
CPT-loaded PAPFVBT Nps were calculated to be 0.03 µM and 0.1 µM respectively, 
corresponding to that CPT-loaded PAPFVBT Nps are 3.3 times less effective than free 
CPT. Having bigger size of PAPFVBT Nps is the main reason of not being effective as 
PPFBT Nps since they could be less efficiently taken up by the cells. 
. 
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Figure 2.37. Percent  cell death with CPT- loaded PAPFVBT Nps, PAPFVBT Nps, 
CPT and DMSO. Huh7 cells were inoculated in 24-well plates. All molecules and their 
DMSO controls were administered to the cells in triplicates with five different 
concentrations of CPT: 1, 0.5, 0.25, 0.125, and 0.0625 μM. After 72 h of incubation, 
SRB assays were generated and the cell death percentages were calculated.  
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CHAPTER 3. CONCLUSION 
In conclusion, a new and simple approach for the combination chemotherapy
 
was 
presented by incorporating a water-insoluble drug camptothecin into the conjugated 
polymer nanoparticles with very high loading efficiency because of the favorable non-
covalent interactions (e.g. hydrophobic effect and π-π interactions) between the 
aromatic backbone of the polymer chains and the drug molecules. The blank and drug 
loaded nanoparticles are uniform in size, size distribution and surface charge.  
 
Table 2. Summary for IC50 values of free drug (CPT), CPT-loaded PPFBT and 
PAPFVBT Nanoparticles. 
Time and dose dependent SRB assay results indicated that these nanoparticles assisted 
the delivery of water-insoluble anticancer drugs into cancer cells (Huh7 cells) in an 
efficient manner leading to effective apoptosis. As it can be seen in Table 2, at the end 
of 48 h, CPT-loaded PPFBT Nps were 9 times more effective than free CPT.  However, 
at the end of 72 h, CPT-loaded PPFBT Nps are 12.5 times more effective than free CPT 
in inducing the apoptosis of Huh7 cells. This is certainly a very impressive finding as 
well as a highly desirable goal to be achieved in the chemotherapy. Noticeably, this new 
imaging-guided drug delivery system does not require a complicated design and 
synthetic methods, needing only one type of polymer which can be synthesized easily 
and acts both as a photostable fluorescent probe, and a matrix to encapsulate the drug 
molecules. 
On the other hand, CPT-loaded PAPFVBT Nps are 3.3 times less effective than free 
CPT because of their bigger size compared to PPFBT Nps that resulted in less 
efficiently taken up by the cells. 
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CHAPTER 4. EXPERIMENTAL 
All reagents were purchased from Sigma–Aldrich Chemical Co. and were used as 
received. 2,7-dibromo-9,9-bis(3-bromo-propyl)-9H-fluorene and 9,9-bis-(3-bromo-
propyl)-2,7-divinyl-9H-fluorene and 2,7-dibromo-9,9-bis-(propenyl)-9H-fluorene were 
synthesized according to the procedure shown in the experimental section. Column 
chromatography with silica gel (Kieselgel 60, 0.063 – 0.200 nm) was used for the 
purification of these monomers. Thin layer chromatography (TLC) was performed by 
using the silica gel plates (Kieselgel 60 F254, 1 mm) to identify the product and the side 
products in the reaction mixture and to determine the purity of the desired product. For 
the structural characterization, nuclear magnetic resonance (NMR, Bruker Avance III 
400 MHz spectrometer) and FT-IR (Bruker TENSOR 27) were performed. CDCl3 and 
DMSO-d6 solvents were used for NMR measurements. In the process of FT-IR 
measurements, the polymer samples were prepared as KBr pellets and each sample of 
nanoparticle dispersions in water was dropped onto the silicon wafer. The data were 
recorded at 25
o
C, in the spectral range of 4000–400 cm-1, by accumulating 256 scans 
with a resolution of 4 cm
-1
. For the optical characterization, a UV–vis 
spectrophotometer (Cary UV–Vis) and a fluorescence spectrophotometer (Cary Eclipse 
Fluorescent spectrophotometer) equipped with a xenon-lamp as the excitation source 
were used. The molecular weight determination of the polymers were done with the use 
of gel permeation chromatography (GPC, Agilent 1200) equipped with Evaporation-
Light-Scattering Detector (ELSD). The column type was ZORBAX PSM 300S, 6.2x250 
mm, 5 μm. The analysis was performed in tetrahydrofuran (THF) (GPC/HPLC grade) at 
a flow rate of 0.6 ml/min. All of the polystyrene samples were 1% solutions in THF 
with the instrument operating at 31
o
C having automotic injection system. Mass-to-
charge ratio was determined via a time measurement by time-of-flight liquid 
chromatography mass spectroscopy ( TOF LC/MS, Agilent 1200/6210). Autoclaved 
ddH2O was used to prepare the nanoparticles. The sizes of the nanoparticles were 
measured by dynamic light scattering (DLS, Zetasizer Nano-ZS). Measurements were 
carried out at 633 nm and the laser, as a light source, was used at room temperature. The 
average particle diameters were calculated by the Marquardt method. The DLS 
measurements were usually repeated at least three times and the average values were 
reported. Morphological characterization was done by atomic force microscope-PSIA 
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(AFM, XE-100E), transmission electron microscopy (TEM, FEI Tecnai G2 F30) and 
scanning electron microscope (SEM, Quanta 200 FEG). 
Preparation of cells and culture: Human hepatocellular carcinoma cell line Huh7 was 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen GIBCO), 
with 10% fetal bovine serum (FBS) (Invitrogen GIBCO), nonessential amino  acids, and 
1% penicillin (Biochrome). Huh7 cells were incubated at 37 °C with 5% CO2. DMSO 
(Sigma) was used as a solvent for Camptothecin (Calbiochem) at a concentration less 
than 1% in the cell culture medium.  
4.1.Synthesis of 2,7-dibromo-9,9-bis(3-bromo-propyl)-9H-fluorene (M1) 
2,7-dibromofluorene (3.0 g, 9.25 mmol) and (0.6 mg, 1.85 mmol) 
tetrabutylammoniumbromide (TBAB) in two-neck round bottom flask (capacity of 100 
mL) were dried under vacuum for 30 min. To this mixture, degassed DMSO (15 mL), 
50% (w/w) NaOH (15 mL) and 1,3-dibromopropene (13 mL, 90 mmol) were added 
respectively. The resulting mixture was stirred under argon for 2 h at room temperature. 
The reaction was exothermic and a bath of ice and water was used to keep it at room 
temperature during 2 h. At the end of 2 h, argon was removed and the final reaction 
mixture was taken to one-neck round bottom flask (capacity of 250 mL), then diethyl 
ether (120 mL) and deionized water (50 mL) were added and stirred for 15 min. By the 
help of seperatory funnel, the above organic layer was separated and washed with the 
order of deionized water (1x100 mL), 2 N HCl (1x100 mL),  deionized water (1x100 
mL), brine solution (3x100 mL) and deionize water (4x100 mL). The final washed 
diethyl ether layer was evaporated under reduced pressure and the resulting product was 
obtained as solid. It was dissolved in minimum amount of cyclohexane/chloroform and 
purified through silica packed column chromatography. Cyclohexane/chloroform (8:2) 
was used as the eluent. For further purification, the desired monomer was dissolved in 
minimum amount of chloroform and precipitated into cold methanol, filtered and dried 
under vacuum. Yield: 1.7227 g, 33 %. 
1
H-NMR (400 MHz, CDCl3, δ ppm): 7.5 (m, 6H), 3.14 (t, 4H), 2.17 (t, 4H), 1.17 (m, 
4H). 
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Scheme 4.1. The structure of 2,7-dibromo-9,9-bis(3-bromo-propyl)-9H-fluorene (M1). 
4.2. Synthesis of 9,9-bis-(3-bromo-propyl)-2,7-divinyl-9H-fluorene (M2) 
2,7-dibromo-9,9-bis(3-bromo-propyl)-9H-fluorene (1.13 g, 2.0 mmol) and 2,6-di-tert-
butylphenol (8 mg, 38 mmol) were dried under vacuum for 30 min. To this mixture, 
degassed toluene (20 mL) and tributylvinyltin (1.45 mL, 5.0 mmol) were added 
respectively. The catalyst, PdCl2(PPh3)2 (56 mg, 0.09 mmol) was added quickly. The 
reaction mixture was stirred and heated at 100
 o
C in an oil bath for 24 h under argon. 
After cooling to room temperature, the mixture was diluted with diethyl ether  and 
treated with 10% (w/w) NaF (20 mL). The resulting mixture was stirred for further 12 h 
at room temperature. At the end of 12 h, obtained insoluble solid was removed by 
filtration. After extraction with distelled water (4x100 mL) and it was dried over 
anhydrous Na2SO4. The solvent was evaporated under reduced pressure. The residue 
was dissolved in minimum amount of cyclohexane-chloroform mixture and purified 
through silica packed column chromatography. Cyclohexane/chloroform (8:2) was used 
as the eluent. For further purification, the desired monomer was dissolved in minimum 
amount of chloroform and precipitated into cold methanol, filtered and dried under 
vacuum. Yield: 0.2761 g, 30 %. 
1
H-NMR (400 MHz, CDCl3, δ ppm): 7.5 (m, 6H), 6.8 (m, 2H), 5.8 (d, 2H), 5.3 (d, 2H) 
3.1 (t, 4H), 2.2 (t, 4H), 1.2 (m, 4H). 
 
Scheme 4.2. The structure of 9,9-bis-(3-bromo-propyl)-2,7-divinyl-9H-fluorene (M2). 
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4.3. Synthesis of 2,7-dibromo-9,9-bis-(propenyl)-9H-fluorene (M3) 
2,7-dibromofluorene (3.0 g, 9.25 mmol) and tetrabutylammoniumbromide (TBAB) (0.6 
g, 1.85 mmol) were dried under vacuum for 30 min. To this mixture, degassed DMSO 
(15 mL), 50% (w/w) NaOH (15 mL), allylbromide (16 ml, 90 mmol) were added 
respectively. The resulting mixture was stirred under argon for 2 h at room temperature. 
After 2 h, t-butyl methyl ether (125 mL) and deionized water (50 mL) were added into 
the mixture and stirred for 15 min. Organic layer was separated and subsequently 
washed with deionized water (50 mL), 2N HCl (50 mL), brine solution (50 mL) and 
deionized water (50 mL), respectively. After extraction, t-butyl methyl ether was 
evaporated under reduced pressure and the monomer was obtained. For the purification 
of the product, silica-packed column chromatography was used with cyclohexane as the 
eluent. The solid was further purified by dissolving in minimum amount of chloroform, 
precipitating into cold methanol. Colorless crystals were collected and dried under 
vacuum. Yield: 3.3 g, 89 %. 
1
H-NMR (400 MHz, CDCl3, δ ppm):7.52 (m, 6H), 5.21 (m, 2H), 4.89 (m, 4H), 2.68 (t, 
4H) 
 
Scheme 4.3. The structure of 2,7-dibromo-9,9-bis-(propenyl)-9H-fluorene (M3). 
4.4. Synthesis of Poly[(9,9- bis{propenyl}fluorenyl-2,7-diyl))-co-(1,4-benzo-{2,1,3}-
thiodiazole)] (PPFBT) 
2,1,3-benzothiadiazole-4,7-bis (boronic acid pinocol ester) (573 mg, 1.47 mmol), 2,7-
dibromo-9,9-bis-(propenyl)-9H-fluorene (M1) (500 mg, 1.47 mmol) and K2CO3 (2.04 g, 
14.7 mmol) were dried under vacuum about 30 min. First the degassed solvents, THF 
(10 mL), water (10 mL) and toluene (10 mL) were added under Argon gas and then, 
catalyst tetrakis (triphenylphosphine) palladium (Pd (PPh3)4) was added quickly. After 3 
h stirring of the mixture under argon at 80–90 °C, the phase transfer catalyst, tetra-n-
butylammonium bromide (TBAB) was added. The stirring was continued for another 
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48h at 80–90 °C to complete the polymerization reaction. The mixture was evaporated 
under vacuum to obtain a solid residue, which was suspended in water; the water 
insoluble particles were collected by suction and dissolved in THF (20 mL) and the 
solution was precipitated into cold methanol (200 mL). The precipitates were collected 
by suction and dried under vacuum for 5 h. Yield: 646 mg, 60 %. 
1
H-NMR (400 MHz, CDCl3, δ ppm): 7.8-8.2 (m, 8H), 5.5 (m, 2H), 4.8-5.1 (m, 4H), 
2.8 (t, 4H).  
FT-IR: (KBr, pellet, υmax(cm
-1
)): 3074 (-CH, w), 2918 (-CH, s), 1455 (C=C-, w).  
GPC: Mn= 4.5 x10
3
 g/mol, Mw= 1.1 x 10
4
 g/mol (Polystyrene as standard). 
 
Scheme 4.4. The structure of poly[(9,9- bis{propenyl}fluorenyl-2,7-diyl))-co-(1,4-
benzo-{2,1,3}-thiodiazole)] (PPFBT). 
4.5. Synthesis of Poly[(9,9-bis{3-bromo-propyl}fluorenyl-2,7-divinylene)-co-(1,4-
benzo-{2,1,3}-thiodiazole)] (PBPFVBT) 
9,9-bis-(3-bromo-propyl)-2,7-divinyl-9H-fluorene (M2) (98 mg, 0.212 mmol), 4,7-
dibromo-2,1,3-benzothiodiazole (62 mg, 0.212 mmol), Pd(OAc)2 (2 mg, 9 μmmol), 
PPh3 (12.85 mg, 49 μmol) and K2CO3 (0.9919 g, 0.007 mol) was degassed with three 
vacuum-argon cycles to remove air. Then, degassed DMF (2 mL) and H2O (0.5 mL) 
were added and the resulting mixture was frozen, evacuated, and thawed three times to 
further remove air. The reaction mixture was vigorously stirred and heated at 100
 o
C in 
an oil bath for 14 h under argon. After cooling to room temperature, the mixture was 
diluted with chloroform and water. The insoluble part was removed by filtering through 
glass filter funnel. Organic layer washed with deionized water and evaporated under 
reduced pressure. The solid product was dissolved in minimum amount of THF and the 
solution was precipitated into cold methanol (200 mL). The red precipitates were 
collected by suction and dried under vacuum. Yield: 65.527 mg, 52% 
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1
H-NMR (400 MHz, CDCl3, δ ppm): 7.5-8.2 (m, 8H), 6.8 (m, 2H), 5.8 (m, 2H) 3.4 (t, 
4H), 2.1 (m, 4H), 0.9 (m, 4H). 
FT-IR: (KBr, pellet, υmax(cm
-1
)): 2961 (C-H, w), 1620 (C=C, w), 1431 (C-C, s), 822 
(C-Br, s) 
 
Scheme 4.5. The structure of poly[(9,9-bis{3-bromo-propyl}fluorenyl-2,7-divinylene)-
co-(1,4-benzo-{2,1,3}-thiodiazole)] (PBPFVBT). 
4.6.Synthesis of Poly[(9,9-bis{3-azido-propyl}fluorenyl-2,7-divinylene)-co-(1,4-
benzo-{2,1,3}-thiodiazole)] (PAPFVBT) 
Poly[(9,9-bis{3-bromo-propyl}fluorenyl-2,7-divinylene)-co-(1,4-benzo-{2,1,3}-
thiodiazole)] (PBPFVBT) (140 mg, 0.235 mmol) was dissolved in DMF (5 mL). Then, 
NaN3 (38.28 mg, 0.589 mmol) was added in the solution. The reaction mixture was 
stirred and heated at 60
 o
C in an oil bath for 24 h under atmosphere. At the end of 
reaction, the solvent was evaporated under reduced pressure. The residue was dissolved 
in minimum amount of THF and the solution was precipitated into cold methanol (200 
mL). The red precipitates were collected by suction and dried under vacuum. Yield: 
101.2 mg, 83%. 
FT-IR: (KBr, pellet, υmax(cm
-1
)): 2961 (C-H, w), 2020 (N3, s), 1620 (C=C, w), 1431 (C-
C, s), 822 (C-Br, s) 
 
Scheme 4.6. The structure of poly[(9,9-bis{3-azido-propyl}fluorenyl-2,7-divinylene)-
co-(1,4-benzo-{2,1,3}-thiodiazole)] (PAPFVBT). 
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4.7. Synthesis of PPFBT Nanoparticles 
PPFBT (2.0 mg, 5.26 x 10
-3
 mmol) was dissolved in THF (5 mL). The resulting solution 
was sonicated for 30 min and then injected rapidly into autoclaved double distilled 
water (50 mL). It was stirred with sonication for further 30 min. THF was removed 
under reduced pressure. The resulting nanoparticle solution was concentrated by 
evaporating its water under reduced pressure to get the concentration of  PPFBT as 0.75 
mg / mL (1.98 x 10
-3
 mmol / mL). 
4.8. Synthesis of Drug Loaded PPFBT Nanoparticles 
For the drug loaded nanoparticles, the drug to polymer ratio was 1:25 (w/w). PPFBT 
(2.0 mg, 5.26 x 10
-3
 mmol) and CPT (0.08 mg, 0.23 x 10
-3
 mmol) ) was dissolved in 
THF (5 mL). The resulting solution was sonicated for 30 min and then injected rapidly 
into autoclaved double distilled water (50 mL). It was stirred with sonication for further 
30 min. THF was removed under reduced pressure. The resulting drug loaded 
nanoparticle solution was filtered through a 0.45 μm syringe filter to remove any free 
drug. Then, it was concentrated by evaporating its water under reduced pressure to get 
the final concentration of  PPFBT as 1.98 x 10
-3
 mmol / mL (0.75 mg / mL) and the 
concentration of CPT as 0.86 x 10
-4
 mmol / mL (0.03 mg / mL). 
4.9.Sulforhodamine B (SRB) Colorimetric Assay for Cytotoxicity Screening for 
Blank and Drug Loaded PPFBT Nanoparticles 
Huh7 cells were inoculated (12000 cells/well in 500 μL) in 24-well plates. The next 
day, the media were refreshed and the CPT and CPT-loaded PPFBT nanoparticles were 
applied in concentrations between 1 and 0.0625 μM in parallel with DMSO-only and 
NP-only treated cells as negative controls. At the end of 48 and 72 hours of treatment  
Huh7 cells were fixed with 150 μL of 10% (w/v) trichloroacetic acid (TCA) and kept at 
+4 °C in the dark for one hour. TCA fixation was terminated by washing the wells with 
ddH2O five times. Air-dried wells were stained with 0.4% sulphorhodamine B (SRB) 
dissolved in 1% acetic acid solution for 10 min in the dark, at room temperature. 
Unbound SRB dye was removed by five  washes with 1% acetic acid, and  protein-
bound and dried SRB dye was then solubilized with 10 mM Tris-Base pH 8. The 
absorbance values were obtained at 515 nm in a microplate reader. The data normalized 
against DMSO-only and NP-only treated wells, which were used as controls in serial 
dilutions.  
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4.10. Hoechst Staining for Blank and Drug Loaded PPFBT Nanoparticles 
Huh7 cells plated on coverslips and treated with CPT, CPT-loaded PPFBT 
nanoparticles, DMSO-only and PPFBT Nps-only for 48 h and 72h were MeOH (100%, 
ice-cold) fixed prior to staining with 1 μg/mL Hoechst 33258. Coverslips destained with 
ddH2O were mounted on glass slides and examined under a fluoresence microscope 
(Nikon ECLIPSE 50i). 
4.11.  Synthesis of PAPFVBT Nanoparticles 
PAPFVBT (1.0 mg, 1.93 x 10
-3
 mmol) was dissolved in THF (5 mL). The resulting 
solution was sonicated for 30 min and then injected rapidly into autoclaved double 
distilled water (50 mL). It was stirred with sonication for further 50 min. THF was 
removed under reduced pressure. The resulting nanoparticle solution was concentrated 
by evaporating its water under reduced pressure to get the concentration of  PPFBT as 
0.40 mg / mL (0.77 x 10
-3
 mmol / mL). 
4.12. Synthesis of Drug Loaded PAPFVBT Nanoparticles 
For the drug loaded nanoparticles, the drug to polymer ratio was 1:25 (w/w). PAPFVBT 
(1.0 mg, 1.93 x 10
-3
 mmol) and CPT (0.04 mg, 0.12 x 10
-3
 mmol) ) was dissolved in 
THF (5 mL). The resulting solution was sonicated for 30 min and then injected rapidly 
into autoclaved double distilled water (50 mL). It was stirred with sonication for further 
50 min. THF was removed under reduced pressure. The resulting drug loaded 
nanoparticle solution was filtered through a 0.45 μm syringe filter to remove any free 
drug. Then, it was concentrated by evaporating its water under reduced pressure to get 
the final concentration of PAPFVBT as 0.55 x 10
-3
 mmol / mL (0.29 mg / mL) and the 
concentration of CPT as 0.29 x 10
-4
 mmol / mL (0.011 mg / mL). 
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4.13. Sulforhodamine B (SRB) Colorimetric Assay for Cytotoxicity Screening for 
Blank and Drug Loaded PAPFVBT Nanoparticles 
Huh7 cells were inoculated (2500 cells/well in 150 μL) in 96-well plates. The next day, 
the media were refreshed and the CPT and CPT-loaded PAPFVBT nanoparticles were 
applied in concentrations between 1 and 0.0625 μM in parallel with DMSO-only and 
PAPFVBT Nps-only treated cells as negative controls. At the end of 72 hours of 
treatment  Huh7 cells were fixed with 50 μL of 10% (w/v) trichloroacetic acid (TCA) 
and kept at +4 °C in the dark for one hour. TCA fixation was terminated by washing the 
wells with ddH2O five times. Air-dried wells were stained with 0.4% sulphorhodamine 
B (SRB) dissolved in 1% acetic acid solution for 10 min in the dark, at room 
temperature. Unbound SRB dye was removed by five  washes with 1% acetic acid, and  
protein-bound and dried SRB dye was then solubilized with 10 mM Tris-Base pH 8. 
The absorbance values were obtained at 515 nm in a microplate reader. The data 
normalized against DMSO-only and NP-only treated wells, which were used as controls 
in serial dilutions.  
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